AGA1
MCID: ALP061
MIFTS: 49

Alopecia, Androgenetic, 1 (AGA1)

Categories: Rare diseases

Aliases & Classifications for Alopecia, Androgenetic, 1

MalaCards integrated aliases for Alopecia, Androgenetic, 1:

Name: Alopecia, Androgenetic, 1 56 13 37 71
Androgenetic Alopecia 56 52 25 17 71
Androgenic Alopecia 52 25
Androgenetic Alopecia; Aga 56
Female Pattern Baldness 25
Female Pattern Alopecia 71
Male Pattern Alopecia 25
Male Pattern Baldness 25
Alopecia Androgenetic 54
Pattern Baldness 25
Aga1 56
Aga 56

Characteristics:

OMIM:

56
Inheritance:
autosomal dominant in males
recessive in females


HPO:

31
alopecia, androgenetic, 1:
Inheritance sex-limited autosomal dominant


Classifications:



External Ids:

OMIM 56 109200
OMIM Phenotypic Series 56 PS203655
MedGen 41 C4049090
SNOMED-CT via HPO 68 278040002 56317004
UMLS 71 C0162311 C0263477 C4049090

Summaries for Alopecia, Androgenetic, 1

Genetics Home Reference : 25 Androgenetic alopecia is a common form of hair loss in both men and women. In men, this condition is also known as male-pattern baldness. Hair is lost in a well-defined pattern, beginning above both temples. Over time, the hairline recedes to form a characteristic "M" shape. Hair also thins at the crown (near the top of the head), often progressing to partial or complete baldness. The pattern of hair loss in women differs from male-pattern baldness. In women, the hair becomes thinner all over the head, and the hairline does not recede. Androgenetic alopecia in women rarely leads to total baldness. Androgenetic alopecia in men has been associated with several other medical conditions including coronary heart disease and enlargement of the prostate. Additionally, prostate cancer, disorders of insulin resistance (such as diabetes and obesity), and high blood pressure (hypertension) have been related to androgenetic alopecia. In women, this form of hair loss is associated with an increased risk of polycystic ovary syndrome (PCOS). PCOS is characterized by a hormonal imbalance that can lead to irregular menstruation, acne, excess hair elsewhere on the body (hirsutism), and weight gain.

MalaCards based summary : Alopecia, Androgenetic, 1, also known as androgenetic alopecia, is related to alopecia and androgenic alopecia. An important gene associated with Alopecia, Androgenetic, 1 is AFA1 (Alopecia, Androgenetic), and among its related pathways/superpathways are Translation Non-genomic (rapid) action of Androgen Receptor and Metabolism of steroid hormones. The drugs Ethanol and Acetylcysteine have been mentioned in the context of this disorder. Affiliated tissues include prostate, ovary and skin, and related phenotypes are alopecia and endocrine/exocrine gland

NIH Rare Diseases : 52 Androgenetic alopecia is a common form of hair loss in both men and women. In men, hair is usually lost in a well-defined pattern, beginning above both temples and is usually referred to as male-pattern baldness . Over time, the hairline recedes to form a characteristic 'M' shape. Hair also thins near the top of the head, often progressing to partial or complete baldness. The pattern of hair loss in women differs from men (female pattern hair loss ). In women, the hair becomes thinner all over the head, and the hairline does not recede. Androgenetic alopecia in women rarely leads to total baldness. A variety of genetic and environmental factors likely play a role in causing this condition. Mutations in the AR gene have also been associated with androgenetic alopecia.

OMIM : 56 Androgenetic alopecia is characterized by a loss of hair from the scalp that follows a defined pattern (Hamilton, 1951). It occurs in women as well as in men. It is caused by a shortening of the anagen (growth) phase and miniaturization of the hair follicle, which results in the formation of progressively thinner, shorter hair (Bergfeld, 1995). In men, the condition is often referred to as male pattern baldness (MPB) and appears to be androgen-dependent (Hamilton, 1942). The condition is hereditary, and follows a pattern that may be consistent with an autosomal dominant trait (Osborn, 1916). Linkage evidence for an autosomal locus on 3q26 (AGA1) has been identified (Hillmer et al., 2008). See 300710 (AGA2) for a discussion of X linkage of androgenetic alopecia. A third locus has been found on chromosome 20p11 (AGA3; 612421). (109200)

Related Diseases for Alopecia, Androgenetic, 1

Diseases in the Alopecia, Androgenetic, 1 family:

Alopecia, Androgenetic, 2 Alopecia, Androgenetic, 3

Diseases related to Alopecia, Androgenetic, 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 375, show less)
# Related Disease Score Top Affiliating Genes
1 alopecia 31.9 SRD5A2 SRD5A1 SHBG AR
2 androgenic alopecia 31.8 TGFB2 SRD5A2 SRD5A1 SHBG CYP19A1 AR
3 impotence 31.0 SRD5A1 SHBG AR
4 hair disease 30.5 SRD5A2 SHBG AR
5 prostatic hyperplasia, benign 30.5 SRD5A2 SRD5A1 SHBG AR
6 prostatic hypertrophy 30.0 SRD5A2 SRD5A1 SHBG CYP19A1 AR
7 hyperandrogenism 29.8 SRD5A1 SHBG CYP21A2 CYP19A1 AR
8 prostate disease 29.7 SRD5A2 SRD5A1 CYP19A1 AR
9 hypogonadism 29.7 SHBG CYP19A1 AR
10 premature ovarian failure 1 29.7 SHBG CYP19A1 AR
11 lipoid congenital adrenal hyperplasia 29.6 SRD5A1 SHBG CYP21A2 CYP19A1
12 polycystic ovary syndrome 29.6 SRD5A1 SHBG CYP21A2 CYP19A1 AR
13 male infertility 29.4 SHBG CYP21A2 CYP19A1 AR
14 gynecomastia 28.9 SRD5A2 SRD5A1 SHBG CYP21A2 CYP19A1 AR
15 endometrial cancer 28.3 STS SHBG CYP19A1 CFLAR AR
16 prostate cancer 27.5 XIAP TGFB2 SRD5A2 SRD5A1 SHBG CYP19A1
17 aspartylglucosaminuria 12.7
18 marie unna congenital hypotrichosis 11.5
19 lysosomal storage disease 11.5
20 hypotrichosis 1 11.4
21 hypotrichosis simplex 11.4
22 fabry disease 11.3
23 angiokeratoma 11.3
24 glucocorticoid resistance, generalized 11.3
25 contractural arachnodactyly, congenital 11.2
26 loeys-dietz syndrome 11.2
27 distal arthrogryposis 11.2
28 muscular disease 11.2
29 muscle tissue disease 11.2
30 lysosomal disease 11.2
31 rapidly involuting congenital hemangioma 10.9
32 alopecia areata 10.8
33 neurofibromatosis, type ii 10.7
34 telogen effluvium 10.7
35 sexual disorder 10.6
36 prostatic adenoma 10.6
37 frontal fibrosing alopecia 10.5
38 lipid metabolism disorder 10.4
39 arteries, anomalies of 10.3
40 retinal dystrophy, iris coloboma, and comedogenic acne syndrome 10.3
41 hyperlipoproteinemia, type iii 10.3
42 lipoprotein quantitative trait locus 10.3
43 diffuse alopecia areata 10.3
44 urolithiasis 10.3
45 infant gynecomastia 10.3
46 contact dermatitis 10.3
47 skin disease 10.3
48 seborrheic dermatitis 10.3
49 inflammatory bowel disease 10.3
50 celiac disease 1 10.3
51 diarrhea 10.3
52 body mass index quantitative trait locus 1 10.3
53 coronary heart disease 1 10.3
54 covid-19 10.3
55 hypertrichosis 10.3
56 folliculitis 10.3
57 gastroesophageal reflux 10.3
58 barrett esophagus 10.3
59 esophagitis 10.3
60 autoimmune disease 10.2
61 hair whorl 10.2
62 atrichia with papular lesions 10.2
63 alopecia, androgenetic, 2 10.2
64 dermatitis, atopic 10.2
65 hyperprolactinemia 10.2
66 central centrifugal cicatricial alopecia 10.2
67 hypothyroidism 10.2
68 personality disorder 10.2
69 dermatitis 10.2
70 allergic contact dermatitis 10.2
71 pustulosis of palm and sole 10.2
72 cerebrovascular disease 10.2
73 psoriasis 10.2
74 47,xyy 10.2
75 48,xyyy 10.2
76 quinquaud folliculitis decalvans 10.2
77 discoid lupus erythematosus 10.2
78 skin carcinoma 10.2
79 esophagitis, eosinophilic, 1 10.2
80 colitis 10.2
81 irritable bowel syndrome 10.2
82 pancreatitis 10.2
83 ulcerative colitis 10.2
84 gender identity disorder 10.1 CYP19A1 AR
85 postmenopausal atrophic vaginitis 10.1 SHBG CYP19A1
86 ovarian cancer 10.1
87 polycystic ovary syndrome 1 10.1
88 alopecia, androgenetic, 3 10.1
89 hypoactive sexual desire disorder 10.1 SHBG CYP19A1
90 osteoporosis 10.1
91 bone mineral density quantitative trait locus 8 10.1
92 bone mineral density quantitative trait locus 15 10.1
93 functional diarrhea 10.1
94 constipation 10.1
95 acute pancreatitis 10.1
96 liver cirrhosis 10.1
97 vasculitis 10.1
98 crohn's disease 10.1
99 hypereosinophilic syndrome 10.1
100 estrogen excess 10.1 SHBG CYP19A1
101 premature ejaculation 10.1 CYP19A1 AR
102 aromatase excess syndrome 10.1 SHBG CYP19A1
103 alcohol dependence 10.0
104 atherosclerosis susceptibility 10.0
105 fibrosis of extraocular muscles, congenital, 1 10.0
106 hypertension, essential 10.0
107 ichthyosis vulgaris 10.0
108 dowling-degos disease 1 10.0
109 vitiligo-associated multiple autoimmune disease susceptibility 6 10.0
110 adrenal hyperplasia, congenital, due to 21-hydroxylase deficiency 10.0
111 galactorrhea 10.0
112 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.0
113 insulin-like growth factor i 10.0
114 alopecia, congenital 10.0
115 adrenoleukodystrophy 10.0
116 spinal and bulbar muscular atrophy, x-linked 1 10.0
117 aging 10.0
118 vitiligo-associated multiple autoimmune disease susceptibility 1 10.0
119 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.0
120 spastic paraplegia, intellectual disability, nystagmus, and obesity 10.0
121 helix syndrome 10.0
122 alexithymia 10.0
123 psychosexual disorder 10.0
124 tonsillitis 10.0
125 nasopharyngitis 10.0
126 rickets 10.0
127 ovarian disease 10.0
128 social phobia 10.0
129 heart disease 10.0
130 conn's syndrome 10.0
131 avoidant personality disorder 10.0
132 keratosis 10.0
133 cystitis 10.0
134 ichthyosis 10.0
135 hyperuricemia 10.0
136 arteriosclerosis 10.0
137 iron metabolism disease 10.0
138 phimosis 10.0
139 irritant dermatitis 10.0
140 mood disorder 10.0
141 glucose metabolism disease 10.0
142 hyperglycemia 10.0
143 tinea capitis 10.0
144 severe combined immunodeficiency 10.0
145 thyroiditis 10.0
146 muscular atrophy 10.0
147 appendicitis 10.0
148 intermediate coronary syndrome 10.0
149 lupus erythematosus 10.0
150 dermatophytosis 10.0
151 lichen planus 10.0
152 diabetes mellitus 10.0
153 adrenomyeloneuropathy 10.0
154 adverse events of 5-alpha-reductase inhibitors 10.0
155 erosive pustular dermatosis of the scalp 10.0
156 pseudopelade of brocq 10.0
157 virilizing ovarian tumor 10.0
158 paresthesia 10.0
159 posttransplant acute limbic encephalitis 10.0
160 inflammatory myopathy with abundant macrophages 10.0
161 genetic alopecia 10.0
162 overgrowth syndrome 10.0
163 malignant sertoli-leydig cell tumor of the ovary 10.0
164 colorectal cancer 10.0
165 adenomyosis 10.0
166 yemenite deaf-blind hypopigmentation syndrome 10.0
167 non-alcoholic fatty liver disease 10.0
168 granulomatous angiitis 10.0
169 churg-strauss syndrome 10.0
170 liver disease 10.0
171 schizoaffective disorder 10.0
172 fatty liver disease 10.0
173 allergic angiitis 10.0
174 pseudovaginal perineoscrotal hypospadias 10.0 SRD5A2 SRD5A1 AR
175 hypospadias 10.0 SRD5A2 SRD5A1 AR
176 mixed gonadal dysgenesis 10.0 SRD5A1 CYP21A2
177 hermaphroditism 10.0 SRD5A2 SHBG AR
178 hidradenitis suppurativa 10.0
179 hidradenitis 10.0
180 hand skill, relative 10.0
181 angina pectoris 10.0
182 sleep apnea 10.0
183 colorectal adenoma 10.0
184 ptosis 10.0
185 cardiac arrest 10.0
186 amenorrhea 10.0
187 basal cell carcinoma 10.0
188 testicular cancer 10.0
189 ovarian cyst 10.0
190 adenoma 10.0
191 cleft lip 10.0
192 esophageal cancer 10.0
193 body mass index quantitative trait locus 11 10.0
194 body mass index quantitative trait locus 9 10.0
195 body mass index quantitative trait locus 8 10.0
196 body mass index quantitative trait locus 4 10.0
197 body mass index quantitative trait locus 10 10.0
198 body mass index quantitative trait locus 7 10.0
199 body mass index quantitative trait locus 12 10.0
200 body mass index quantitative trait locus 14 10.0
201 body mass index quantitative trait locus 18 10.0
202 cholangiocarcinoma 10.0
203 body mass index quantitative trait locus 19 10.0
204 body mass index quantitative trait locus 20 10.0
205 microscopic colitis 10.0
206 crohn's colitis 10.0
207 non-alcoholic steatohepatitis 10.0
208 portal hypertension 10.0
209 gastroparesis 10.0
210 acute cystitis 10.0
211 heart septal defect 10.0
212 hepatitis b 10.0
213 hepatitis 10.0
214 food allergy 10.0
215 gallbladder cancer 10.0
216 pancreatic ductal adenocarcinoma 10.0
217 lynch syndrome 10.0
218 intrahepatic cholangiocarcinoma 10.0
219 gastrointestinal system disease 10.0
220 myeloid leukemia 10.0
221 achalasia 10.0
222 dysphagia 10.0
223 sertoli cell tumor 9.9 CYP19A1 AR
224 complete androgen insensitivity syndrome 9.9 SHBG CYP19A1 AR
225 precocious puberty, male-limited 9.9 CYP21A2 CYP19A1
226 precocious puberty 9.9 CYP21A2 CYP19A1
227 hypercholesterolemia, familial, 1 9.9
228 testicular germ cell tumor 9.9
229 seizures, scoliosis, and macrocephaly/microcephaly syndrome 9.9
230 adrenal carcinoma 9.9
231 myopathy 9.9
232 arteriolosclerosis 9.9
233 testicular germ cell cancer 9.9
234 central congenital hypothyroidism 9.9
235 germ cells tumors 9.9
236 persistent mullerian duct syndrome 9.9 SRD5A2 CYP21A2
237 alopecia totalis 9.8
238 total anomalous pulmonary venous return 1 9.8
239 breast cancer 9.8
240 pilomatrixoma 9.8
241 ige responsiveness, atopic 9.8
242 systemic lupus erythematosus 9.8
243 myositis 9.8
244 pancreatitis, hereditary 9.8
245 peutz-jeghers syndrome 9.8
246 pulmonary atresia with ventricular septal defect 9.8
247 raynaud disease 9.8
248 schizophrenia 9.8
249 tetralogy of fallot 9.8
250 thrombocytopenic purpura, autoimmune 9.8
251 cystic fibrosis 9.8
252 pancreatic cancer 9.8
253 gallbladder disease 1 9.8
254 budd-chiari syndrome 9.8
255 stroke, ischemic 9.8
256 leukemia, acute myeloid 9.8
257 branchiootic syndrome 1 9.8
258 cervical cancer 9.8
259 kawasaki disease 9.8
260 gastric cancer 9.8
261 cholangitis, primary sclerosing 9.8
262 dengue virus 9.8
263 streptococcus pneumonia 9.8
264 dengue shock syndrome 9.8
265 exanthem 9.8
266 infective endocarditis 9.8
267 immunoglobulin alpha deficiency 9.8
268 aphasia 9.8
269 pain agnosia 9.8
270 atrial fibrillation 9.8
271 salmonellosis 9.8
272 bone disease 9.8
273 bone resorption disease 9.8
274 endometrial hyperplasia 9.8
275 pelvic inflammatory disease 9.8
276 endocarditis 9.8
277 bacterial infectious disease 9.8
278 microinvasive gastric cancer 9.8
279 glucose intolerance 9.8
280 short bowel syndrome 9.8
281 microcephaly 9.8
282 hemiplegia 9.8
283 placenta praevia 9.8
284 respiratory failure 9.8
285 gestational diabetes 9.8
286 visual epilepsy 9.8
287 dengue hemorrhagic fever 9.8
288 alcoholic hepatitis 9.8
289 acute leukemia 9.8
290 carotid stenosis 9.8
291 typhoid fever 9.8
292 cholestasis 9.8
293 eclampsia 9.8
294 patent foramen ovale 9.8
295 polyneuropathy 9.8
296 peptic esophagitis 9.8
297 sclerosing cholangitis 9.8
298 alcohol use disorder 9.8
299 thrombocytopenia 9.8
300 ventricular septal defect 9.8
301 neuritis 9.8
302 status epilepticus 9.8
303 atrial heart septal defect 9.8
304 hepatitis c 9.8
305 cholecystitis 9.8
306 rectum cancer 9.8
307 nodular hidradenoma 9.8
308 gastroenteritis 9.8
309 cervicitis 9.8
310 hemoglobinopathy 9.8
311 endometriosis 9.8
312 adenocarcinoma 9.8
313 myelitis 9.8
314 ischemia 9.8
315 purpura 9.8
316 carotid artery disease 9.8
317 breast disease 9.8
318 gallbladder adenocarcinoma 9.8
319 vaginal discharge 9.8
320 hidradenoma 9.8
321 sebaceous adenocarcinoma 9.8
322 intestinal disease 9.8
323 eccrine acrospiroma 9.8
324 clear cell hidradenoma 9.8
325 spiradenoma 9.8
326 congestive heart failure 9.8
327 follicular adenoma 9.8
328 double outlet right ventricle 9.8
329 inherited metabolic disorder 9.8
330 myositis ossificans 9.8
331 active peptic ulcer disease 9.8
332 peptic ulcer disease 9.8
333 eccrine porocarcinoma 9.8
334 septic arthritis 9.8
335 intestinal obstruction 9.8
336 herpes zoster 9.8
337 subacute delirium 9.8
338 gas gangrene 9.8
339 cholangitis 9.8
340 meningitis 9.8
341 pulmonary embolism 9.8
342 placental abruption 9.8
343 hemorrhoid 9.8
344 polyarteritis nodosa 9.8
345 hypoglycemia 9.8
346 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 9.8
347 coronary artery aneurysm 9.8
348 haemophilus influenzae 9.8
349 lymphangiectasis 9.8
350 transverse myelitis 9.8
351 raynaud phenomenon 9.8
352 febrile seizures 9.8
353 headache 9.8
354 seizure disorder 9.8
355 syncope 9.8
356 acute transverse myelitis 9.8
357 idiopathic acute transverse myelitis 9.8
358 46,xy sex reversal 2 9.8 CYP21A2 CYP19A1
359 sebaceous gland disease 9.8 SHBG CYP21A2 AR
360 cortisone reductase deficiency 9.8 SRD5A2 SRD5A1 CYP21A2
361 hypogonadotropic hypogonadism 9.7 SHBG CYP19A1 AR
362 turner syndrome 9.7 SHBG CYP21A2 AR
363 breast cyst 9.7 TGFB2 CYP19A1
364 androgen insensitivity syndrome 9.7 SRD5A2 SRD5A1 SHBG AR
365 androgen insensitivity, partial 9.7 SRD5A1 SHBG CYP19A1 AR
366 luteoma 9.7 SHBG CYP21A2 CYP19A1
367 steroid inherited metabolic disorder 9.7 SHBG CYP21A2 CYP19A1
368 kallmann syndrome 9.6 STS SRD5A2 SHBG
369 anovulation 9.5 SRD5A1 SHBG CYP21A2 CYP19A1
370 transsexualism 9.4 SRD5A2 CYP21A2 CYP19A1 AR
371 antley-bixler syndrome 9.4 CYP21A2 CYP19A1
372 46,xy sex reversal 9.4 SRD5A2 CYP21A2 CYP19A1 AR
373 pseudohermaphroditism 9.2 SRD5A2 SRD5A1 CYP21A2 CYP19A1 AR
374 disorders of sexual development 9.2 SRD5A2 SHBG CYP21A2 CYP19A1 AR
375 cryptorchidism, unilateral or bilateral 9.1 STS SRD5A2 SRD5A1 SHBG CYP19A1 AR

Graphical network of the top 20 diseases related to Alopecia, Androgenetic, 1:



Diseases related to Alopecia, Androgenetic, 1

Symptoms & Phenotypes for Alopecia, Androgenetic, 1

Human phenotypes related to Alopecia, Androgenetic, 1:

31 (showing 1, show less)
# Description HPO Frequency HPO Source Accession
1 alopecia 31 HP:0001596

Symptoms via clinical synopsis from OMIM:

56
Hair:
early baldness

Clinical features from OMIM:

109200

MGI Mouse Phenotypes related to Alopecia, Androgenetic, 1:

45 (showing 1, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.17 AR CFLAR CYP19A1 SRD5A1 SRD5A2 TGFB2

Drugs & Therapeutics for Alopecia, Androgenetic, 1

Drugs for Alopecia, Androgenetic, 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 69, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ethanol Approved Phase 4 64-17-5 702
2
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
3
Histamine Approved, Investigational Phase 4 51-45-6 774
4
Cetirizine Approved Phase 4 83881-51-0 2678
5
Cysteine Approved, Nutraceutical Phase 4 52-90-4 5862
6 Anti-Infective Agents Phase 4
7 Anti-Infective Agents, Local Phase 4
8 Fenugreek Phase 4
9 Fenugreek seed meal Phase 4
10 N-monoacetylcystine Phase 4
11 Histamine Antagonists Phase 4
12 Histamine H1 Antagonists, Non-Sedating Phase 4
13 Anti-Allergic Agents Phase 4
14 Histamine H1 Antagonists Phase 4
15
Histamine Phosphate Phase 4 51-74-1 65513
16 Neurotransmitter Agents Phase 4
17
Dutasteride Approved, Investigational Phase 3 164656-23-9 152945 6918296
18
Zinc Approved, Investigational Phase 1, Phase 2 7440-66-6 32051
19
Nitric Oxide Approved Phase 1, Phase 2 10102-43-9 145068
20
Acetylcholine Approved, Investigational Phase 2 51-84-3 187
21
Bimatoprost Approved, Investigational Phase 2 155206-00-1 5311027
22
Valproic acid Approved, Investigational Phase 2 99-66-1 3121
23
Vitamin C Approved, Nutraceutical Phase 1, Phase 2 50-81-7 5785 54670067
24
Maleic acid Experimental, Investigational Phase 1, Phase 2 110-17-8, 110-16-7 444972
25 Trace Elements Phase 1, Phase 2
26 Nutrients Phase 1, Phase 2
27 Micronutrients Phase 1, Phase 2
28 Adjuvants, Immunologic Phase 2
29 Protective Agents Phase 2
30 Radiation-Protective Agents Phase 2
31 Antiviral Agents Phase 2
32 Ammonium trichloro(dioxoethylene-O,O'-)tellurate Phase 2
33 Chelating Agents Phase 1, Phase 2
34 Zinc Supplement Phase 1, Phase 2
35 Respiratory System Agents Phase 1, Phase 2
36 Antioxidants Phase 1, Phase 2
37 Anti-Asthmatic Agents Phase 1, Phase 2
38 Endothelium-Dependent Relaxing Factors Phase 1, Phase 2
39 Bronchodilator Agents Phase 1, Phase 2
40 abobotulinumtoxinA Phase 2
41 Cholinergic Agents Phase 2
42 Botulinum Toxins Phase 2
43 Botulinum Toxins, Type A Phase 2
44
protease inhibitors Phase 2
45 HIV Protease Inhibitors Phase 2
46 Proteasome Inhibitors Phase 2
47 Androgens Phase 2
48 Ophthalmic Solutions Phase 2
49 Psychotropic Drugs Phase 2
50 Anticonvulsants Phase 2
51 Mitogens Phase 1, Phase 2
52 Immunologic Factors Phase 1, Phase 2
53 Complement Factor H Phase 1, Phase 2
54 Complement System Proteins Phase 1, Phase 2
55 Immunosuppressive Agents Phase 1, Phase 2
56
Sodium citrate Approved, Investigational 68-04-2
57
Estradiol Approved, Investigational, Vet_approved 50-28-2 5757
58
Polyestradiol phosphate Approved 28014-46-2
59
Citric acid Approved, Nutraceutical, Vet_approved 77-92-9 311
60
Vitamin D Approved, Nutraceutical, Vet_approved 1406-16-2
61 Citrate
62 Calcium, Dietary
63 Anti-Bacterial Agents
64 Estradiol 17 beta-cypionate
65 Estradiol 3-benzoate
66 Anesthetics
67 Vitamins
68 Calciferol
69
Calcium Nutraceutical 7440-70-2 271

Interventional clinical trials:

(showing 133, show less)
# Name Status NCT ID Phase Drugs
1 Evaluating the Efficacy of Different Platelet Rich Plasma (PRP) Treatment Regimens in the Management of Androgenetic Alopecia: an Investigator-initiated, Single-center, Single-blinded, Prospective, Randomized Clinical Trial Unknown status NCT02999737 Phase 4
2 Minoxidil in Treatment of Androgenetic Alopecia Completed NCT04090801 Phase 4 Topical minoxidil 5% in 90% ethanol and 5% propylene glycol;Topical minoxidil 5% in pure ethanol alone
3 Efficacy and Safety of Furocyst in Patients With Poly Cystic Ovary Syndrome Completed NCT02789488 Phase 4
4 Efficacy and Tolerability of N-Acetyl- Cysteine for Treatment of The Early-onset Androgenetic Alopecia in Men Recruiting NCT04209803 Phase 4 Minoxidil 5% topically and oral NAC 600 mg
5 the Effect of Adipose Derived Stem Cells Combined With Platelet Rich Plasma Versus Platelet Rich Plasma Alone on Follicular Unit Extraction Hair Transplantion in Male Androgenic Alopecia: Clinical Trial Recruiting NCT03388840 Phase 4
6 Topical Cetirizine Gel Versus Minoxidil 5% Gel in Treatment of Androgenetic Alopecia Not yet recruiting NCT04293822 Phase 4 Cetirizine;Minoxidil
7 The Use of 5mg Finasteride Versus 200mg Spironolactone and Topical 5% Minoxidil in Treating Postmenopausal Female Androgenetic Alopecia Withdrawn NCT02483195 Phase 4 5% Minoxidil;200mg Spironolactone;5mg Finasteride
8 BLIND RANDOMIZED COMPARATIVE STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MESOTHERAPY MINOXIDIL HAIR WITH 0.5% / 2ML VERSUS PLACEBO IN THE TREATMENT OF FEMALE ANDROGENETIC ALOPECIA Unknown status NCT01655108 Phase 3 Minoxidil;Saline
9 A Multicentre, Randomized, Double-blind, Parallel-group, Controlled Study, to Assess the Efficacy and Safety of P-3074 Cutaneous Spray, Solution, in the Treatment of Male Pattern Baldness Completed NCT03004469 Phase 3 P-3074;Finasteride;P-3074 Vehicle;Finasteride Placebo
10 Evaluating the Efficacy of Topical Herbal Solution on the Treatment of Androgenetic Alopecia and Comparison With Minoxidil 5%: A Double-Blind, Randomized, Clinical Trial Study Completed NCT03753113 Phase 3 Topical Herbal Solution;Topical Minoxidil 5%
11 A Prospective Study of Sexual Function in Men Taking Dutasteride for the Treatment of Androgenetic Alopecia Completed NCT02014584 Phase 3 Dutasteride;Placebo
12 A Phase 3 Multi-Center Parallel Design Clinical Trial to Compare the Efficacy and Safety of 5% Minoxidil Foam vs. Vehicle in Females for the Treatment of Female Pattern Hair Loss (Androgenetic Alopecia) Completed NCT01226459 Phase 3 5% Minoxidil Topical Foam;Vehicle Topical Foam
13 An Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of Dutasteride 0.5mg Once Daily for 6 Months in the Treatment of Male Subjects With Androgenetic Alopecia (Norwood-Hamilton Classification Type IIIv, IV and V) Completed NCT00441116 Phase 3 Dutasteride 0.5mg oral tablets
14 A Phase 3 Multi-Center Parallel Design Clinical Trial to Compare the Efficacy and Safety of 5 % Minoxidil Foam vs. 2 % Minoxidil Solution in Females for the Treatment of Female Pattern Hair Loss - Androgenetic Alopecia (MINALO3004, NCT01145625) Completed NCT01145625 Phase 3 5% Minoxidil;2% Minoxidil
15 A Prospective, Randomized, Controlled, Double-Blind Study That Evaluates the Safety and Efficacy of Three Active REVIAN Caps Versus a Non-Active REVIAN Cap (Sham) in Participants With Pattern Hair Loss (Androgenic Alopecia) Completed NCT04019795 Phase 3
16 A Double-Blind, Placebo-Controlled, Multicenter Study To Examine the Effects of Finasteride 1 MG on Serum Prostate-Specific Antigen in Men With Androgenetic Alopecia Completed NCT00396175 Phase 3 MK0906, finasteride / Duration of Treatment : 48 Weeks;Comparator : placebo (unspecified) / Duration of Treatment : 48 Weeks
17 Investigator-initiated Single Blind, Two-armed, Randomized Phase 3 Clinical Trial to Compare Efficacy of 5% Minoxidil Topical Foam (5% Mtf) Once Daily Versus 2% Minoxidil Topical Solution (2% Mts) Twice Daily in Application on Females With Slightly to Moderate Androgenetic Alopecia Concerning Hair Volume Completed NCT00958750 Phase 3 minoxidil
18 Study ARI114264: A Long-Term Study of the Safety and Efficacy of Dutasteride in the Treatment of Male Subjects With Androgenetic Alopecia Completed NCT01831791 Phase 3 Dutasteride 0.5 mg
19 Efficacy of 3% Minoxidil Versus Combined 3% Minoxidil and 0.1% Finasteride for Male Pattern Hair Loss: a Randomized, Double-blinded, Comparative Study Completed NCT01391156 Phase 3 3%Minoxidil lotion;3% Minoxidil with 0.1% Finasteride lotion
20 A Study of the Efficacy and Safety of Multiple Doses of Dutasteride Versus Placebo and Finasteride in the Treatment of Male Subjects With Androgenetic Alopecia Completed NCT01231607 Phase 3 1mg Finasteride active;0.02mg dutasteride;0.1mg dutasteride;0.5mg dutasteride;Finasteride placebo;Dutasteride placebo
21 A Double-Blind, Randomized, Placebo-Controlled Trial of the Efficacy and Safety of 5 Percent Minoxidil Foam in the Treatment of Androgenetic Alopecia in Males Completed NCT00151515 Phase 3 minoxidil
22 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of 0.15% & 0.25% Concentrations of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia Active, not recruiting NCT03742518 Phase 2, Phase 3 Topical SM04554 solution;Topical SM04554 solution;Topical vehicle solution
23 H-36371: Finasteride as a Method of Managing Testosterone-Induced Erythrocytosis Withdrawn NCT02548117 Phase 3 Finasteride
24 A Phase 2 Multicenter, Randomized, Placebo-Controlled, Parallel Group Dose-Ranging Study to Evaluate the Safety and Efficacy of Topical NEOSH101 in the Treatment of Androgenetic Alopecia in Men Unknown status NCT00471510 Phase 2 tetrapeptide aldehyde proteasome inhibitor (NEOSH101)
25 The Clinical Effects of HSC (Hair Stimulating Complex) on Hair Growth in Androgenetic Alopecia: A Phase I/II Clinical Trial Unknown status NCT01501617 Phase 1, Phase 2
26 A Prospective Multicentric Open Label Randomized Bio-Interventional Phase I/II Pilot Study To Evaluate The Safety And Efficacy Of Autologous Human Platelet Lysate (HPL) For Treatment Of Androgenetic Alopecia (AGA) Unknown status NCT01643629 Phase 1, Phase 2
27 An Efficacy and Safety Pilot Study Comparing 5% Monoxidil Milky Lotion Versus 5% Minoxidil Solution in Treatment of AGA Unknown status NCT01650272 Phase 1, Phase 2 5% MInoxidil milky lotion;5% Minoxidil solution
28 Phase 2 Study of Topical AS101 for the Treatment of FAGA (Female Androgenetic Alopecia) in Menopause Women Unknown status NCT00418249 Phase 2 AS101
29 A Multi-center, Randomized, Controlled, Double-blind Study That Evaluates a Low Level Laser Therapy Over-the-counter at Home Device, Theradome™ LH80 PRO vs a Sham Device, for Promoting Hair Growth in Males Diagnosed With Androgenetic Alopecia Unknown status NCT02528552 Phase 2
30 A Prospective Multicentric Open Label Randomized Bio-Interventional Phase I/II Pilot Study To Evaluate Safety & Efficacy Of Autologous Human Platelet Lysate For Treatment Of Androgenetic Alopecia In Patients Undergoing Hair Transplant Unknown status NCT01644422 Phase 1, Phase 2
31 A Pilot Study of the Efficacy in Treatment of Female Pattern Hair Loss Using 5% Minoxidil Solution Combinded With Oral Chelated Zinc Supplement Unknown status NCT01662089 Phase 1, Phase 2 15 mg Chelate zinc supplement;Placebo drug supplement
32 Safety and Efficacy of Nitric Oxide Gel in Promoting Hair Growth in Male Human Subjects With Androgenetic Alopecia Unknown status NCT01347957 Phase 1, Phase 2
33 A Randomised, Double-blind, Placebo-controlled Phase 2 Trial of FOL-005 to Investigate Efficacy on Hair Growth on Scalp Skin in Healthy Volunteers Unknown status NCT03467412 Phase 2 FOL-005;Placebo
34 A Phase 2, Multicenter, Randomized, Double-Blind Study of SM04554 Applied Topically to the Scalp of Male Subjects With Androgenetic Alopecia (AGA) Analyzed by Biopsy of the Scalp Prior To and Post Dosing Completed NCT02503137 Phase 2 Topical SM04554 solution;Topical Vehicle solution
35 A Multi-center, Phase 2 Study of Ji Gami(TM) CN That Evaluates the Efficacy and Safety of ex Vivo-cultured, Expanded, Occipital Autologous Dermal and Epidermal Cells, Injected Into the Hair Loss Area of the Scalp of Male and Female Subjects With Alopecia Completed NCT01669746 Phase 2
36 A Multi-center, Phase 2 Study of Ji Gami(TM) CN That Evaluates the Efficacy and Safety of Injections of ex Vivo Expanded Cultured Occipital Autologous Dermal and Epidermal Cells Into the Hair Loss Area of the Scalp of Subjects Completed NCT01451190 Phase 2
37 A Phase 2 Study to Evaluate and Compare the Efficacy of Injections of Cultured Occipital Autologous Dermal and Epidermal Cells vs Dermal Cells, Where Cells Are Expanded ex Vivo From Plucked Scalp, Into the Hair Loss Area of the Scalp of Subjects. Completed NCT01451177 Phase 2
38 A Phase 2 Study to Evaluate and Compare the Efficacy of Injections of ex Vivo Expanded Cultured Occipital Autologous Dermal and Epidermal Cells Into the Hair Loss Area of the Scalp of Subjects Completed NCT01451151 Phase 2
39 A Phase 2 Study to Evaluate and Compare the Efficacy of Injections of ex Vivo Expanded Cultured Occipital Autologous Dermal and Epidermal Cells vs Dermal Cells Into the Hair Loss Area of the Scalp of Subjects Completed NCT01451138 Phase 2
40 A Phase 2 Study to Evaluate and Compare the Efficacy of Injections of Ex Vivo Expanded Cultured Occipital Autologous Dermal and Epidermal Cells vs. Dermal Cells Into the Hair Loss Area of the Scalp of Subjects and Synergy With Application of Topical Minoxidil Completed NCT01451125 Phase 2
41 A Phase 2 Study to Evaluate and Compare the Efficacy of Injections of Ex Vivo Expanded Cultured Occipital Autologous Dermal and Epidermal Cells vs. Dermal Cells Into the Hair Loss Area of the Scalp of Subjects Completed NCT01451112 Phase 2
42 A Phase 2 Randomized Study to Evaluate and Compare the Efficacy of Injections of Ex Vivo Expanded Cultured Occipital Autologous Dermal Cells Into the Balding Scalp of Subjects With Hair Loss Completed NCT01451099 Phase 2
43 A Phase 2 Randomized Study to Evaluate and Compare the Efficacy of a 1 Time Injection vs. Repeat Injections of ex Vivo Expanded Cultured Autologous Occipital Dermal and Epidermal Cells (Same Day as Cell Culture Harvest) Into the Balding Scalp of Subjects With Hair Loss Completed NCT01451073 Phase 2
44 A Phase 2 Randomized Study to Evaluate and Compare the Efficacy of Injections of ex Vivo Expanded Cultured Occipital Autologous Dermal and Epidermal Cells vs. Dermal Cells Into the Balding Scalp of Subjects With Hair Loss Completed NCT01451047 Phase 2
45 A Phase 2 Randomized Study to Evaluate and Compare the Efficacy of a 1 Time Injection vs. Repeat Injections of ex Vivo Expanded Cultured Autologous Occipital Dermal and Epidermal Cells (Day After Cell Culture Harvest) Into the Balding Scalp of Subjects With Hair Loss Completed NCT01451021 Phase 2
46 A Prospective, Single Center, Open Label, Proof of Principle Study to Assess the Efficacy and Safety of 150 Units of Botulinum Toxin-A Intra-Muscular Injection in the Prevention of Hair Loss in Men With Androgenetic Alopecia Completed NCT00965640 Phase 2 Botulinum Toxin - A injections
47 A Phase 2 Multicenter, Randomized, Placebo- and Comparator-Controlled, Double-Blind Parallel Group Study to Evaluate the Safety and Efficacy of Topical NEOSH101 in the Treatment of Androgenetic Alopecia in Men Completed NCT00418730 Phase 2 tetrapeptide aldehyde proteasome inhibitor (NEOSH101)
48 A Phase 2, Multicenter, Randomized, Double-Blind, Controlled Study to Evaluate the Safety and Efficacy of Cortexolone 17α-Propionate (CB-03-01) Solution 5%, Minoxidil Solution 5%, and Vehicle Solution, Applied Twice-daily for 26 Weeks in Males With Androgenetic Alopecia (AGA) Completed NCT02279823 Phase 2 CB-03-01 solution;Minoxidil Solution 5%;Placebo solution
49 A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle- Controlled Study of the Safety, Tolerability, and Efficacy of 0.15% and 0.25% Concentrations of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA) Completed NCT02275351 Phase 2 SM04554;Vehicle
50 Randomized, Single-centre, Double-blind, Placebo-controlled, Phase I / IIa Study to Evaluate the Safety and Efficacy of Human Autologous Hair Follicle Dermal Sheath Cup Cells (DSCC) in Women and Men With Androgenetic Alopecia. Completed NCT01286649 Phase 1, Phase 2
51 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2A Study of Setipiprant Tablets in Androgenetic Alopecia in Males Completed NCT02781311 Phase 2 Setipiprant;Placebo;Finasteride
52 Adipose Tissue Derived Stem Cell Based Hair Restoration Therapy for Androgenetic Alopecia Completed NCT02865421 Phase 2 stem cells;platelet rich plasma
53 Evaluation of the Efficacy of Hcap Formula Nutrition Supplement for Treatment of Men With Androgenic Alopecia: A Prospective, Randomized, Double-Blind, Placebo-Controlled Clinical Trial Completed NCT02150187 Phase 2
54 A Single-center, Active-controlled, Randomized, Double-blind, Proof of Concept Clinical Trial to Explore the Efficacy and Safety of DA-4001 After Topical Application in Male Patients With Androgenetic Alopecia Completed NCT02280603 Phase 1, Phase 2 DA-4001C;5% minoxidil
55 Extension Study for the Evaluation of Finasteride in the Treatment of Chronic Central Serous Chorioretinopathy Completed NCT01227993 Phase 1, Phase 2 Finasteride
56 A Safety and Efficacy Study of Bimatoprost in Men With Androgenic Alopecia (AGA) Completed NCT01904721 Phase 2 Bimatoprost Solution 1;Bimatoprost Solution 2;Bimatoprost Vehicle
57 Investigator-Initiated, Double Blind, Two-Armed, Placebo-Controlled, Randomized Clinical Trial With an Open-Label Extension Phase, to Investigate Efficacy of 5% Minoxidil Topical Foam Twice Daily in Men With Androgenetic Alopecia in the Temple and Vertex Region Concerning Hair Volume Over 24 / 104 Weeks Completed NCT01319370 Phase 2 Minoxidil;vehicle of 5% Minoxidil topical foam
58 Safety and Efficacy Study of Bimatoprost in the Treatment of Men With Androgenic Alopecia Completed NCT01325337 Phase 2 bimatoprost Formulation A;bimatoprost Formulation B;bimatoprost Formulation C;bimatoprost vehicle solution;minoxidil 5% solution
59 Topical Bimatoprost Effect on Androgen Dependent Hair Follicles Completed NCT02170662 Phase 2 Bimatoprost;Placebo
60 A Randomized Controlled Trial Comparing Platelet Rich Plasma (PRP) to Minoxidil Foam for Treatment of Androgenic Alopecia in Women Completed NCT03488108 Phase 1, Phase 2 Minoxidil Foam
61 The Efficacy and Safety of Topical Valproic Acid in Preventing Hair Loss Completed NCT01548066 Phase 2 Valproic Acid;Control placebo
62 A Randomized, Double-Blind, Active-controlled, Parallel, Phase II Study to Evaluate Efficacy and Safety of ENERGI-F701 Solution in Female Subjects With Hair Loss Recruiting NCT03351322 Phase 2 ENERGI-F701;Regaine
63 Biocellular Regenerative Therapy in Hair Loss: Use of High Density Platelet-Rich Plasma Concentrates and Cell-Enriched Emulsified Adipose-Derived Tissue Stromal Vascular Fraction Recruiting NCT02849470 Phase 1, Phase 2
64 The Safety and Efficacy of Fractional Ablative 10, 600nm CO2 Laser-assisted Treatments for Male Pattern Hair Loss: a Randomized Cohort Study Comparing Stand-alone Laser Treatment, Laser Assisted Drug Delivery of Minoxidil 2% Solution , and Laser Assisted Drug Delivery of Minoxidil 2% Solution Plus Self-administration of Minoxidil 5% at Home. Recruiting NCT03852992 Phase 2 Post-Laser Minoxidil 2%;At-Home Minoxidil 5%;Post-laser 5mg minoxidil;Post-laser 10mg minoxidil;Post-laser 20mg minoxidil
65 An Open-Label Safety, Tolerability, and Efficacy Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical Solution Active, not recruiting NCT03495817 Phase 2 ATI-50002
66 Clinical Treatment of Alopecia Areata With Stem Cell Educator Therapy and Oral Minoxidil Not yet recruiting NCT04011748 Phase 2
67 A Randomized, Double-blind, Placebo-controlled Clinical Trial Investigating the Effect of Autologous Platelet-rich Plasma in Subjects With Androgenetic Alopecia. Withdrawn NCT03048461 Phase 2 Placebo
68 Evaluating the Efficacy of Microneedling in the Treatment of Androgenetic Alopecia- Pilot Study Unknown status NCT02154503 Phase 1
69 Split Wound Comparison of Trichophytic Closure Techniques for Donor Site in Hair Transplantation Unknown status NCT01655602 Phase 1
70 Evaluation of Local Pharmacokinetics and Tolerability of Bimatoprost Applied Topically to the Scalp of Male Patients With Androgenetic Alopecia Completed NCT02848300 Phase 1 Bimatoprost 1% Formulation A;Bimatoprost 1% Formulation B
71 An Evaluation of the Bioequivalence of Five 0.1 mg GI198745/Dutasteride Soft Gelatin Capsules Compared to One 0.5 mg GI198745/Dutasteride Gelatin Capsules in Healthy Male Volunteers Completed NCT01929330 Phase 1 GI198745 0.1 mg;GI198745 0.5 mg
72 Pharmacokinetics/ Pharmacodynamics and Safety of DA-4001 in Healthy Male Subjects With Androgenic Alopecia Completed NCT02824380 Phase 1 DA-4001 H;DA-4001 L
73 Study Evaluating the Association of CAG Repeat Polymorphisms and Finasteride Response in Women With Androgenetic Alopecia Completed NCT01052870 Phase 1 Finasteride
74 A Within-subject, Randomized, Evaluator-blinded, Vehicle-controlled Study to Assess the Photosensitization Potential of Finasteride Cutaneous Solution(P-3074) in Human Subjects Completed NCT02791243 Phase 1 Finasteride 0.25%;Placebo for Finasteride 0.25%;Negative Control
75 A Randomized, Open-label, Single-dose, Crossover Study to Evaluate the Pharmacokinetics and Safety of AD-208 Recruiting NCT04214808 Phase 1 AD-208;Avodart Soft Capsule 0.5mg
76 Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Bimatoprost Topical Solution in the Treatment of Androgenetic Alopecia in Men Terminated NCT02676310 Phase 1 Bimatoprost
77 Pharmacogenomic Study of Androgenetic Alopecia Unknown status NCT01227031
78 A Prospective Double Blind, Placebo Controlled Study to Assess the Efficacy of Platelet-Rich Plasma on the Treatment of Androgenetic Alopecia Unknown status NCT02393040
79 A Pilot Randomized, Double-blind, Placebo-controlled Clinical Trial to Obtain Preliminary Data on Efficacy and Safety in the Application of PRGF-Endoret by Mesotherapy, in the Treatment of Male and Female Androgenetic Alopecia of Over 6 Months Duration. Unknown status NCT01885676
80 Efficacy and Safety of Platelet Rich Plasma in Androgenetic Alopecia: A Double-Blind, Randomized, Placebo Controlled Trial Unknown status NCT02074943
81 Nanofat Grafting for Treatment of Androgenetic Alopecia Unknown status NCT03506503
82 Prospective Safety and Efficacy Evaluation of Hairstetics™ Anchoring System for Hair Extensions in Female Pattern Hair Loss Unknown status NCT02316418
83 The Study for New Effect of Roxithromycin on Androgenetic Alopecia. Unknown status NCT00197379 roxithromycin
84 Computer-Assisted Hair Implantation Using ARTAS System VS Manual Implantation Technique Hair Restoration Study Unknown status NCT02914587
85 A Randomized, Double -Blind,, Sham-Device-Controlled, Multicenter, 24-Week Clinical Trial to Evaluate the Safety and Effectiveness of the iRestore ™ Hair Rejuvenation System in the Treatment of Male and Female Androgeneticalopecia Unknown status NCT01686295
86 A European Network for the Investigation of Gender Incongruence Unknown status NCT01072825
87 Androgenetic Alopecia in Fabry Disease Completed NCT01295008
88 Microarray Analysis of Scalp Biopsies in Subjects With Androgenetic Alopecia Before and After the Use of Topical Minoxidil Completed NCT01309191 Minoxidil
89 Subcutaneous Transplantation of Autologous Cell Enriched Adipose Tissue For Follicular Niche Stimulation in Early Stage Alopecia Androgenetica (STYLE): a Randomized, Blinded, Controlled Trial Completed NCT02503852
90 A Randomized, Double-Blind Clinical Trial to Evaluate the Safety and Efficacy of the HairMax LaserComb 2009, 12 Beam Model For The Treatment of Androgenetic Alopecia in Females Completed NCT01016964
91 A Randomized, Double-Blind, Control Device Clinical Trial to Evaluate the Safety and Efficacy of the HairMax LaserComb 2009, 7 Beam Model: For the Treatment of Androgenetic Alopecia in Males Completed NCT00947505
92 A Randomized, Double-Blind Clinical Trial to Evaluate the Safety and Efficacy of the HairMax LaserComb 2009, 9 Beam Model: For the Treatment of Androgenetic Alopecia in Females Completed NCT00981461
93 A Randomized, Double-Blind, Control Device Clinical Trial to Evaluate the Safety and Efficacy of the HairMax LaserComb 2009, 9 & 12 Beam Models: For the Treatment of Androgenetic Alopecia in Males Completed NCT00947219
94 A Monocentric, Double-blind, Randomized, Active- and Placebo-controlled Split-scalp Study to Evaluate the Clinical Effectiveness of Platelet-rich Plasma (PRP) in the Treatment of Androgenetic Alopecia Completed NCT02591355
95 Effect of Pumpkin Seed Oil on Hair Growth in Men With Androgenetic Alopecia Completed NCT01852487
96 The Effect of Microneedling With Low Energy Laser in Androgenic Alopecia Patients. Completed NCT03723369
97 Point-of-Care Adipose-derived Cells for Hair Growth Completed NCT02729415
98 Application and Evaluation of PRP on the Therapy for Hair Loss Disorder Completed NCT02087319
99 Minoxidil Response Testing in Males With Androgenetic Alopecia Completed NCT02198261 5% minoxidil topical foam
100 Minoxidil Response Testing in Females With Female Pattern Hair Loss Completed NCT02206802 5% minoxidil topical foam
101 Multicenter, Open Label Clinical Trial to Evaluate the Effect and Tolerability of Minoxidil 2% Solution and Botanical Hair Solution Regimen in Women With Thinning Hair and Female Pattern Hair Loss/Androgenic Alopecia (Ludwig I and II) Completed NCT02460497 Treatment: Minoxidil 2% / Botanical Hair Solution for Women
102 Multicenter, Open Label Clinical Trial to Evaluate the Effect and Tolerability of Minoxidil 5% Foam and Botanical Hair Solution Regimen in Men With Thinning Hair and Male Pattern of Hair Loss/Androgenic Alopecia (Norwood III & IV) Completed NCT02460289 Treatment: Minoxidil 5% / Botanical Hair Solution for Men
103 Adipose-derived Stromal Vascular Fraction (SVF) Injections to Stimulate Hair Regrowth for Androgenetic Alopecia Completed NCT02626780
104 The Effect of Allogeneic Human Adipose Derived Stem Cell Component Extract on Androgenic Alopecia Completed NCT02594046
105 Clinical Study for the Assessment of the Hair Growth Efficacy and Safety of a Cosmetic Investigational Product, After Repeated Applications for 24 Weeks, Under Normal Conditions of Use, in the Asian Adult Subjects With Androgenic Alopecia Completed NCT03676400
106 An Open Label, Multi-centre, Non-interventional Post-marketing Surveillance to Monitor the Safety and Effectiveness of AVODART® Administered in Korean Androgenetic Alopecia Patients According to the Prescribing Information Completed NCT01004809 Dutasteride
107 The Growth of Human Scalp Hair Mediated By Visible Red Light Laser and LED Sources. Completed NCT01437163
108 Evaluation of the Efficacy of the Cosmetic Lotion M.P.A.F. (Mixture of Paraffin, Alcohol and Fur) MEXIS PATENT in the Treatment of Androgenetic Alopecia by Decreasing of Hair Loss and Strengthening and Thickening of Hair in Males and Females. Completed NCT01701271
109 A Novel Approach to Treating Androgenetic Alopecia in Females With Low Level Laser Therapy Completed NCT01967277
110 A Randomized, Double-blind Clinical Trial to Evaluate the Safety and Efficacy of the X5 HairLaser for the Treatment of Androgenetic Alopecia in Males Completed NCT02067260
111 Assessment of the Role of the JAK-STAT Pathway in the Pathogenesis of Male Androgenetic Alopecia Completed NCT03694067
112 The Utility of Platelet Rich Plasma in Hair Loss Completed NCT03376581 Early Phase 1
113 Optimizing Parameters for Long-pulsed Nd:YAG Laser for Reducing Hair Shaft Diameter at the Donor Area for Hair Transplantation Completed NCT03394235
114 Serum Endocan Levels in Polycystic Ovary Syndrome: a Possible Marker of Angiogenic Dysfunction Completed NCT03019679
115 "iRestore" Light Therapy Apparatus in the Treatment of Androgenetic Alopecia: A Randomized, Double-blind, Self-comparison, Sham Device-controlled, Multicenter Trial Completed NCT03331003
116 Safety and Efficacy of Computer-Assisted vs. Manual Hair Follicle Harvest: A Comparative Hair Count Study Completed NCT00926211
117 The Effect of Platelet Rich Plasma on Non-scarring Alopecia Completed NCT03689452 Normal saline
118 Is Serum Anti-Mullerian Hormone (AMH) Level Associated With Body Weight, Glycemic and Lipidemic Markers in Adolescent Girls With Polycystic Ovaries? Completed NCT01856894
119 Efficacy of Platelet-Rich Plasma Therapy for Androgenetic Alopecia: A Systematic Review and Meta-analysis Recruiting NCT04191005
120 The Efficacy of Visible Red Light for Promoting the Growth of Human Scalp Hair for Both Male and Female - An Open-label Study Recruiting NCT03938948
121 Using Indirect Cold Atmospheric Pressure Plasma (Plasma Activate Liquid) for the Treatment of Hair Loss Recruiting NCT04379752
122 Biocellular Regenerative Therapy in Treating Scaring Alopecias and Alopecia Areata: Use of High Density Platelet-Rich Plasma Concentrates and Cell-Enriched Emulsified Adipose-Derived Tissue Stromal Vascular Fraction (AD-tSVF) Recruiting NCT03078686
123 A Prospective, Double-blind, Split-body, Randomized Controlled Trial to Assess the Efficacy of Low Level Laser Therapy for Pigmentary Disorders Recruiting NCT04308421
124 Prevalence of Hirsutism in Turkey: Data of The Dermatoendocrinology Study Group Recruiting NCT04292587
125 A Comparative Study of Homoeopathic Treatment Versus Integrated Approach of Homoeopathy and Yoga in the Treatment of Menstrual Disorders in Females With Polycystic Ovarian Syndrome. Recruiting NCT03579303
126 Evaluating PAI-1 Expression in the Hair Follicles of Patients With Non-scarring Hair Loss. Enrolling by invitation NCT02548689
127 Role of Vitamin D in Androgenetic Alopecia Not yet recruiting NCT03154528
128 Follicular Revival in Treatment-resistant Alopecia Areata: Evaluating Use of Micro-needling Not yet recruiting NCT04341363
129 Evaluating the Efficacy of Platelet-rich Plasma Therapy in the Treatment of Androgenic Alopecia Not yet recruiting NCT03474718 Early Phase 1
130 The Role of Trichoscopy in the Preliminary Diagnosis of Immunobollous Diseases Not yet recruiting NCT03478072
131 Sexual Dysfunction in Female Patients With Adult Acne Vulgaris Not yet recruiting NCT03879369
132 An Evaluation of the Effect of the Erchonia ML Scanner (MLS) on the Treatment of Androgenic Alopecia in Females Terminated NCT01292746
133 Minoxidil Dose Response Study in Females Identified Through IVD Testing as Non-Responders to 5% Topical Minoxidil Withdrawn NCT02486848 5% Topical Minoxidil Solution;15% Topical Minoxidil Solution

Search NIH Clinical Center for Alopecia, Androgenetic, 1

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Alopecia, Androgenetic, 1 cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Alopecia, Androgenetic, 1:
RepliCel Hair-01 (RCH-01), hair follicle-derived mesenchymal stem cells for treatment of androgenetic alopecia
Embryonic/Adult Cultured Cells Related to Alopecia, Androgenetic, 1:
Hair follicle mesenchymal stem cells (RepliCel Hair-01)

Genetic Tests for Alopecia, Androgenetic, 1

Anatomical Context for Alopecia, Androgenetic, 1

MalaCards organs/tissues related to Alopecia, Androgenetic, 1:

40
Prostate, Ovary, Skin, Heart, Testes, Breast, Endothelial

Publications for Alopecia, Androgenetic, 1

Articles related to Alopecia, Androgenetic, 1:

(showing 1455, show less)
# Title Authors PMID Year
1
Genome-wide scan and fine-mapping linkage study of androgenetic alopecia reveals a locus on chromosome 3q26. 56 61
18304493 2008
2
The hairless gene in androgenetic alopecia: results of a systematic mutation screening and a family-based association approach. 56 61
11966690 2002
3
Androgenetic alopecia in heterozygous carriers of a mutation in the human hairless gene. 56 61
10827399 2000
4
The inheritance of common baldness: two B or not two B? 56 61
6512048 1984
5
Genetic analysis of male pattern baldness and the 5alpha-reductase genes. 56
9620288 1998
6
Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17. 56
7849715 1994
7
Evidence for a single gene effect causing polycystic ovaries and male pattern baldness. 56
8334753 1993
8
Patterned loss of hair in man; types and incidence. 56
14819896 1951
9
Novel anti-prostate cancer curcumin analogues that enhance androgen receptor degradation activity. 61 54
19663790 2009
10
Recent positive selection of a human androgen receptor/ectodysplasin A2 receptor haplotype and its relationship to male pattern baldness. 54 61
19373488 2009
11
Evaluation of androgen receptor gene as a candidate gene in female androgenetic alopecia. 54 61
19538365 2009
12
Androgen receptor copy number variation and androgenetic alopecia: a case-control study. 61 54
19340294 2009
13
Finasteride treatment and neuroactive steroid formation. 54 61
19655698 2009
14
Value of hormonal levels in patients with male androgenetic alopecia treated with finasteride: better response in patients under 26 years old. 61 54
18363752 2008
15
Men with Kennedy disease have a reduced risk of androgenetic alopecia. 61 54
17596176 2007
16
Baldness and the androgen receptor: the AR polyglycine repeat polymorphism does not confer susceptibility to androgenetic alopecia. 61 54
17256155 2007
17
[Premature androgenetic alopecia in adult male with nonclassic 21-OH deficiency. A novel nonsense CYP21A2 mutation (Y336X) in 2 affected siblings]. 61 54
17145028 2006
18
A new look at the 5alpha-reductase inhibitor finasteride. 61 54
16834758 2006
19
The E211 G>A androgen receptor polymorphism is associated with a decreased risk of metastatic prostate cancer and androgenetic alopecia. 61 54
15824176 2005
20
Solubilization and solid-state characterization of a poorly soluble 5-alpha reductase inhibitor. 61 54
15285330 2004
21
Ketocazole as an adjunct to finasteride in the treatment of androgenetic alopecia in men. 61 54
14729013 2004
22
Testosterone metabolism in human skin cells in vitro and its interaction with estradiol and dutasteride. 54 61
14528059 2003
23
Analysis of genetic polymorphisms of steroid 5alpha-reductase type 1 and 2 genes in Korean men with androgenetic alopecia. 61 54
12670724 2003
24
Male-pattern baldness is common in men with X-linked recessive ichthyosis. 54 61
14571075 2003
25
Acne: effect of hormones on pathogenesis and management. 61 54
12358558 2002
26
Steroid sulfatase in the human hair follicle concentrates in the dermal papilla. 61 54
11886493 2001
27
Androgen responsive genes as they affect hair growth. 61 54
11399535 2001
28
The novel drug CS-891 inhibits 5alpha-reductase activity in freshly isolated dermal papilla of human hair follicles. 61 54
11125319 2000
29
[Hormonal profile in men with premature androgenic alopecia]. 54 61
10953626 2000
30
[Treatment of androgenetic alopecia in the man using systemic 5 alpha-reductase inhibition]. 61 54
9879479 1998
31
Delayed telogen replacement in a boy's scalp. 54 61
9873170 1998
32
Different levels of 5alpha-reductase type I and II, aromatase, and androgen receptor in hair follicles of women and men with androgenetic alopecia. 54 61
9284093 1997
33
Hormonal status in postmenopausal androgenetic alopecia. 61 54
1478763 1992
34
A comprehensive review of biochemical factors in herbs and their constituent compounds in experimental studies on alopecia. 61
32360043 2020
35
Accelerated hair growth by combining thread monofilament and minoxidil in female androgenetic alopecia. 61
31789457 2020
36
Racial variations in COVID-19 deaths may be due to androgen receptor genetic variants associated with prostate cancer and androgenetic alopecia. Are anti-androgens a potential treatment for COVID-19? 61
32333494 2020
37
Health Risks Associated with Long-Term Finasteride and Dutasteride Use: It's Time to Sound the Alarm. 61
32202088 2020
38
Correction to: Comparative Study to Evaluate Tolerability of Topical 5% Minoxidil Novel Formulation and Alcohol-Based Conventional Solutions in Treatment of Androgenetic Alopecia in Indian Men: Randomized Double-Blind Study. 61
32350810 2020
39
Randomized trial of electrodynamic microneedling combined with 5% minoxidil topical solution for treating androgenetic alopecia in Chinese males and molecular mechanistic study of the involvement of the Wnt/β-catenin signaling pathway. 61
32412314 2020
40
Comparative Study to Evaluate Tolerability of Topical 5% Minoxidil Novel Formulation and Alcohol-Based Conventional Solutions in Treatment of Androgenetic Alopecia in Indian Men: Randomized Double-Blind Study. 61
32277388 2020
41
Topical finasteride for the treatment of male androgenetic alopecia and female pattern hair loss: a review of the current literature. 61
32538225 2020
42
The Efficacy and Safety of Finasteride Combined with Topical Minoxidil for Androgenetic Alopecia: A Systematic Review and Meta-analysis. 61
32166351 2020
43
Favorable effects of microneedling on long-standing androgenetic alopecia in an elderly man: A case report. 61
32500595 2020
44
Androgenetic alopecia: effects of oral finasteride on hormone profile, reproduction and sexual function. 61
32052367 2020
45
The effectiveness of combination therapies for androgenetic alopecia: A systematic review and meta-analysis. 61
32478968 2020
46
Clinical experience on follicular unit extraction megasession for severe androgenetic alopecia. 61
31529675 2020
47
Cross Sectional Quality of Life Assessment in Patients with Androgenetic Alopecia. 61
32520416 2020
48
Study of serum vitamin D levels in men with premature androgenetic alopecia. 61
32516435 2020
49
Evaluation of quality of life of patients with hirsutism among Turkish women: A single-center cross-sectional study. 61
32564506 2020
50
Spironolactone in Dermatology: Uses in Acne, Hidradenitis Suppurativa, Female Pattern Baldness, and Hirsutism. 61
32571540 2020
51
The hydroxypropyl-β-cyclodextrin-minoxidil inclusion complex improves the cardiovascular and proliferative adverse effects of minoxidil in male rats: Implications in the treatment of alopecia. 61
32378360 2020
52
Platelet-Rich Plasma and its Use for Cicatricial and Non-Cicatricial Alopecias: A Narrative Review. 61
32557337 2020
53
Cerebral Venous Sinus Thrombosis Associated with Dutasteride Use. 61
32469180 2020
54
Erosive pustular dermatosis of the scalp: a multicentre study. 61
31954062 2020
55
Low-dose oral minoxidil as treatment for non-scarring alopecia: a systematic review. 61
32516434 2020
56
Erosive pustular dermatosis of the scalp: causes and treatments. 61
32516510 2020
57
Clascoterone as a novel treatment for androgenetic alopecia. 61
32421862 2020
58
Androgenetic alopecia is associated with increased scalp hardness. 61
31944388 2020
59
Global expression profile and global genome methylation signatures in male patients with androgenetic alopecia. 61
31876348 2020
60
Androgenetic Alopecia Present in the Majority of Hospitalized COVID-19 Patients - the "Gabrin sign". 61
32446821 2020
61
Efficacy and safety of very low dose oral minoxidil 1.25mg in male androgenetic alopecia. 61
32492469 2020
62
RF-Mesotherapy With Dutasteride: A Future Alternative Treatment for Androgenetic Alopecia. 61
32416936 2020
63
Stromal vascular fraction-enriched platelet-rich plasma therapy reverses the effects of androgenetic alopecia. 61
31541565 2020
64
Cell Enriched Autologous Fat Grafts to Follicular Niche Improves Hair Regrowth in Early Androgenetic Alopecia. 61
32020170 2020
65
MR Imaging of Hair and Scalp for the Evaluation of Androgenetic Alopecia. 61
32378681 2020
66
Progenitor-cell-enriched micrografts as a novel option for the management of androgenetic alopecia. 61
31643084 2020
67
Dexpanthenol may be a novel treatment for male androgenetic alopecia: Analysis of nine cases. 61
32255530 2020
68
5-Alpha reductase inhibitors in androgenetic alopecia: Shifting paradigms, current concepts, comparative efficacy, and safety. 61
32279398 2020
69
A randomized, single-blinded, vehicle-controlled study of a topical active blend in the treatment of androgenetic alopecia. 61
32473084 2020
70
Platelet-rich plasma injections in the treatment of male androgenetic alopecia: A randomized placebo-controlled crossover study. 61
31532574 2020
71
Plasma Zinc Levels in Males with Androgenetic Alopecia as Possible Predictors of the Subsequent Conservative Therapy's Effectiveness. 61
32456296 2020
72
Efficacy of Platelet Rich Plasma Intradermal Injections for Androgenetic Alopecia Treatment in Males: A Before and After Study. 61
32401718 2020
73
Novel topical booster enhances follicular sulfotransferase activity in patients with androgenetic alopecia: a new strategy to improve minoxidil response. 61
32432358 2020
74
A randomized, double-blind, vehicle-controlled clinical study of hair regeneration using adipose-derived stem cell constituent extract in androgenetic alopecia. 61
32420695 2020
75
At the crossroads of 2 alopecias: Androgenetic alopecia pattern of hair regrowth in patients with alopecia areata treated with oral Janus kinase inhibitors. 61
32382642 2020
76
Investigation of optimum transplant and extraction density based on the data from the donor area of Chinese androgenetic alopecia patients: a multicenter, retrospective study. 61
32375571 2020
77
Physiology and Medical Treatments for Alopecia. 61
32312501 2020
78
Androgen sensitivity gateway to COVID-19 disease severity. 61
32412125 2020
79
Migration Inhibitory Factor in Conditioned Medium from Human Umbilical Cord Blood-Derived Mesenchymal Stromal Cells Stimulates Hair Growth. 61
32481584 2020
80
Platelet-rich plasma as a therapy for androgenic alopecia: a systematic review and meta-analysis. 61
32410524 2020
81
Post-finasteride syndrome: An emerging clinical problem. 61
32435662 2020
82
Efficacy and safety of a new formulation kit (shampoo + lotion) containing anti-inflammatory and antioxidant agents to treat hair loss. 61
32134172 2020
83
The use of phosphodiesterase inhibitors for the treatment of alopecia. 61
30935254 2020
84
Getting under the skin of hair aging: the impact of the hair follicle environment. 61
32358903 2020
85
Current advances in stem cell-based therapies for hair regeneration. 61
32439260 2020
86
Is there a therapeutic effect of botulinum toxin on scalp alopecia? Physiopathology and reported cases: A systematic review of the literature. 61
32536461 2020
87
Vanillic Acid Stimulates Anagen Signaling via the PI3K/Akt/β-Catenin Pathway in Dermal Papilla Cells. 61
32394669 2020
88
QR 678 & QR678 Neo Vs PRP-A randomised, comparative, prospective study. 61
32333510 2020
89
A review of the treatment of male pattern hair loss 61
32066284 2020
90
Efficacy of non-surgical treatments for androgenetic alopecia in men and women: a systematic review with network meta-analyses, and an assessment of evidence quality. 61
32250713 2020
91
Serum 25 hydroxyvitamin D levels in alopecia areata, female pattern hair loss, and male androgenetic alopecia in a Chinese population. 61
32275116 2020
92
What does androgenetic alopecia have to do with COVID-19? An insight into a potential new therapy. 61
32237190 2020
93
Systematic Review of Platelet-Rich Plasma Use in Androgenetic Alopecia Compared with Minoxidil®, Finasteride®, and Adult Stem Cell-Based Therapy. 61
32295047 2020
94
Recurring transient lymphadenopathy after microneedling with platelet-rich plasma for androgenetic alopecia. 61
32278805 2020
95
Stratifying clinical response to adjuvant platelet-rich plasma in patients with androgenetic alopecia. 61
32248528 2020
96
The Effect of Intradermal Botulinum Toxin on Androgenetic Alopecia and Its Possible Mechanism. 61
32339707 2020
97
Comment on 'Androgenetic alopecia is associated with increased scalp hardness': role of phosphodiesterase inhibitors? 61
32335955 2020
98
Hyperuricemia is associated with androgenetic alopecia in men: A cross-sectional case-control study. 61
32281237 2020
99
5α-reductase inhibitors in men aged 50 years or older with androgenetic alopecia: a retrospective study. 61
32320771 2020
100
Androgenetic Alopecia in Gender Minority Patients. 61
32115134 2020
101
Topical Antiandrogen Therapies for Androgenetic Alopecia and Acne Vulgaris. 61
31832993 2020
102
New effects of caffeine on corticotropin-releasing hormone (CRH)-induced stress along the intrafollicular classical hypothalamic-pituitary-adrenal (HPA) axis (CRH-R1/2, IP3 -R, ACTH, MC-R2) and the neurogenic non-HPA axis (substance P, p75NTR and TrkA) in ex vivo human male androgenetic scalp hair follicles. 61
32271938 2020
103
The Physician's Guide to Platelet-Rich Plasma in Dermatologic Surgery Part II: Clinical Evidence. 61
31770154 2020
104
Autologous platelet-rich plasma therapy for pattern hair loss: A systematic review. 61
31452328 2020
105
Impact of dutasteride on spermatogenesis and oxidative status in rats. 61
32240114 2020
106
Polycystic ovarian syndrome: Correlation between hyperandrogenism, insulin resistance and obesity. 61
31733195 2020
107
Androgenetic alopecia; An attempt to target microinflammation. 61
32052538 2020
108
Finasteride Counseling for Male Androgenetic Alopecia Should Reflect Updated Findings on Prostate Cancer Risk. 61
32258059 2020
109
Early-onset androgenetic alopecia in China: a descriptive study of a large outpatient cohort. 61
32188323 2020
110
Microneedling improves minoxidil response in androgenetic alopecia patients by upregulating follicular sulfotransferase enzymes. 61
32492993 2020
111
Low-level laser therapy and narrative review of other treatment modalities in androgenetic alopecia. 61
32162134 2020
112
Androgenetic alopecia-Perspective from patients in a Singaporean tertiary Dermatology center. 61
32185827 2020
113
Effective combination therapy with high concentration of Minoxidil and Carboxygas in resistant Androgenetic alopecia: Report of nine cases. 61
32162774 2020
114
Growth factor concentrations in platelet-rich plasma for androgenetic alopecia: An intra-subject, randomized, blinded, placebo-controlled, pilot study. 61
31984508 2020
115
Severity of androgenetic alopecia associated with poor sleeping habits and carnivorous eating and junk food consumption-A web-based investigation of male pattern hair loss in China. 61
32061036 2020
116
Autologous activated platelet-rich plasma (AA-PRP) and non-activated (A-PRP) in hair growth: a retrospective, blinded, randomized evaluation in androgenetic alopecia. 61
32011196 2020
117
Platelet-Rich Plasma and Stem Cells for Hair Growth: A Review of the Literature. 61
31111157 2020
118
Functional complexity of hair follicle stem cell niche and therapeutic targeting of niche dysfunction for hair regeneration. 61
32171310 2020
119
Extract of Plumbago zeylanica enhances the growth of hair follicle dermal papilla cells with down-regulation of 5α-reductase type II. 61
32125089 2020
120
The Physician's Guide to Platelet-Rich Plasma in Dermatologic Surgery Part I: Definitions, Mechanisms of Action, and Technical Specifications. 61
31714381 2020
121
Monofilament threads in treatment of female hair loss. 61
31619089 2020
122
Preliminary results of the use of scalp microneedling in different types of alopecia. 61
31254437 2020
123
The Role of Diet as an Adjuvant Treatment in Scarring and Nonscarring Alopecia. 61
32258051 2020
124
Treatment of Male-Pattern Alopecia with Platelet-Rich Plasma. 61
32258052 2020
125
Fully automated chip-based nanoelectrospray ionization-mass spectrometry as an effective tool for rapid and high-throughput screening of 5α-reductase inhibitors. 61
32008083 2020
126
PPAR-γ signalling as a key mediator of human hair follicle physiology and pathology. 61
31769892 2020
127
Large-Scale Beard Extraction Enhances the Cosmetic Results of Scalp Hair Restoration in Advanced Androgenetic Alopecia in East Asian Men: A Retrospective Study. 61
31784942 2020
128
Trichologic response of platelet-rich plasma in androgenetic alopecia is maintained during combination therapy. 61
29580860 2020
129
Platelet-rich plasma associated with hair transplants for the treatment of androgenetic alopecia showed no benefits. 61
32103552 2020
130
Female Androgenetic Alopecia: An Update on Diagnosis and Management. 61
31677111 2020
131
'The psychosocial burden of alopecia areata and androgenetica': a cross-sectional multicentre study among dermatological out-patients in 13 European countries. 61
31465592 2020
132
Prolonged use of finasteride-induced gonadal sex steroids alterations, DNA damage and menstrual bleeding in women. 61
31967291 2020
133
Trichoscopic evaluation of frontal hairline recession in Egyptian female patients. 61
32048427 2020
134
Can we halt male androgenetic alopecia progression without antiandrogenic drugs? 61
31846191 2020
135
Oral Minoxidil: A Possible New Therapy for Androgenetic Alopecia. 61
31994933 2020
136
Exosomes: A New Effective Non-Surgical Therapy for Androgenetic Alopecia? 61
32501792 2020
137
Formononetin: Novel Deal for Androgenetic Alopecia. 61
32086106 2020
138
A prospective study examining isolated acne and acne with hyperandrogenic signs in adult females. 61
31868042 2020
139
Do Kimchi and Cheonggukjang Probiotics as a Functional Food Improve Androgenetic Alopecia? A Clinical Pilot Study. 61
31385480 2020
140
Androgenetic Alopecia: Relationship to Anthropometric Indices, Blood Pressure and Life-Style Habits. 61
32104040 2020
141
Very-low-dose oral minoxidil in male androgenetic alopecia: A study with quantitative trichoscopic documentation. 61
31520662 2020
142
The Clinical Efficacy and Safety of Autologous Activated Platelet-Rich Plasma Injection in Androgenetic Alopecia. 61
32021857 2020
143
Excellent response to mesotherapy as adjunctive treatment in male androgenetic alopecia. 61
31066492 2020
144
Topical ketoconazole for the treatment of androgenetic alopecia: A systematic review. 61
31858672 2020
145
Increased DHEAS and Decreased Total Testosterone Serum Levels in a Subset of Men with Early-Onset Androgenetic Alopecia: Does a Male PCOS-Equivalent Exist? 61
32148484 2020
146
Clinical Efficacy of a Topical Compounded Formulation in Male Androgenetic Alopecia: Minoxidil 10%, Finasteride 0.1%, Biotin 0.2%, and Caffeine Citrate 0.05% Hydroalcoholic Solution. 61
32023218 2020
147
The Effect of the Fractional Carbon Dioxide Laser on Improving Minoxidil Delivery for the Treatment of Androgenetic Alopecia. 61
32099624 2020
148
Autologous Micrografts from Scalp Tissue: Trichoscopic and Long-Term Clinical Evaluation in Male and Female Androgenetic Alopecia. 61
32071919 2020
149
Randomized trial of electrodynamic microneedle combined with 5% minoxidil topical solution for the treatment of Chinese male Androgenetic alopecia. 61
29028377 2020
150
Effectiveness and safety of oral dutasteride for male androgenetic alopecia in real clinical practice: A descriptive monocentric study. 61
31820540 2020
151
Reply to: "Very-low-dose oral minoxidil in male androgenetic alopecia: A study with quantitative trichoscopic documentation". 61
31520659 2020
152
Platelet-Rich Plasma and Its Utilities in Alopecia: A Systematic Review. 61
31211715 2020
153
Fibrosing alopecia in a pattern distribution. 61
31926219 2020
154
Human Derived Immortalized Dermal Papilla Cells With a Constant Expression of Testosterone Receptor. 61
32269992 2020
155
Increased Preauricular Wrinkles in Frontal Fibrosing Alopecia Compared to Age-Matched Controls: A Prospective Study of 64 Patients. 61
32021855 2020
156
Isolating Dermal Papilla Cells from Human Hair Follicles Using Microdissection and Enzyme Digestion. 61
32314210 2020
157
Types and Treatment of Hair Loss in Men and Women. 61
32102074 2020
158
Predictive Metagenomic Profiling, Urine Metabolomics, and Human Marker Gene Expression as an Integrated Approach to Study Alopecia Areata. 61
32411613 2020
159
Post-finasteride syndrome: a surmountable challenge for clinicians. 61
32033719 2020
160
A randomized, investigator-blinded, controlled, split-scalp study of the efficacy and safety of a 1550-nm fractional erbium-glass laser, used in combination with topical 5% minoxidil versus 5% minoxidil alone, for the treatment of androgenetic alopecia. 61
30982177 2019
161
In silico analysis of gene expression data from bald frontal and haired occipital scalp to identify candidate genes in male androgenetic alopecia. 61
31511972 2019
162
The effect of platelet-rich plasma injection in the treatment of androgenetic alopecia. 61
30895745 2019
163
Transdermal finasteride delivery via powder-carrying microneedles with a diffusion enhancer to treat androgenetic alopecia. 61
31689460 2019
164
Dilation of Multiple Eccrine Ducts as a Highly Specific Marker for Cicatricial Alopecia. 61
31764231 2019
165
Non-ablative radio frequency for the treatment of androgenetic alopecia. 61
31855270 2019
166
In Vitro and In Vivo Assessment of Metabolic Drug Interaction Potential of Dutasteride with Ketoconazole. 61
31835695 2019
167
Meta-analysis of photobiomodulation for the treatment of androgenetic alopecia. 61
31746251 2019
168
A Study of Correlation of Angiographic Evaluation of Coronary Artery Disease with Androgenetic Alopecia - TricoHeart Study. 61
32030055 2019
169
The diagnosis of androgenetic alopecia in children: Considerations of pathophysiological plausibility. 61
31168786 2019
170
[Therapeutic effect of Impatiens balsamina, Lawsonia inermis L. and Henna on androgenetic alopecia in mice]. 61
31852654 2019
171
Alopecia areata multiplex following autologous dermal micrograft injection for treatment of androgenetic alopecia. 61
31120162 2019
172
Amyloid-Associated Alopecia: A Reappraisal Including Its Pathophysiology. 61
30839340 2019
173
Hair distribution width - a novel trichoscopy parameter for hair miniaturization in androgenetic alopecia. 61
31066933 2019
174
Types of hairline recession in androgenetic alopecia and perceptions of aging in Asian males. 61
30888056 2019
175
Platelet-Rich Plasma as a Treatment for Androgenetic Alopecia. 61
30882509 2019
176
Efficacy and safety of a new 10% topical minoxidil versus 5% topical minoxidil and placebo in the treatment of male androgenetic alopecia: a trichoscopic evaluation. 61
31403367 2019
177
Quantitative proteomic analysis of dermal papilla from male androgenetic alopecia comparing before and after treatment with low-level laser therapy. 61
30843235 2019
178
Androgenetic alopecia: combing the hair follicle signaling pathways for new therapeutic targets and more effective treatment options. 61
31456448 2019
179
Platelet-Rich Plasma Therapy for Androgenetic Alopecia. 61
31543541 2019
180
Physiopathology and current treatments of androgenetic alopecia: Going beyond androgens and anti-androgens. 61
31400254 2019
181
Efficacy of Platelet-rich Plasma for Treating Androgenic Alopecia of Varying Grades. 61
31228018 2019
182
Effectiveness and safety of low-dose oral minoxidil in male androgenetic alopecia. 61
31054970 2019
183
Investigation on Microecology of Hair Root Fungi in Androgenetic Alopecia Patients. 61
31240449 2019
184
Pediatric androgenetic alopecia: A review. 61
31415838 2019
185
Efficacy of platelet-rich plasma in androgenetic alopecia patients. 61
30393988 2019
186
Androgenetic alopecia and microneedling: Every needling is not microneedling. 61
30905794 2019
187
An overview of herbal alternatives in androgenetic alopecia. 61
30980598 2019
188
Frequency of the Types of Alopecia at Twenty-Two Specialist Hair Clinics: A Multicenter Study. 61
31559256 2019
189
Low-level laser therapy for the treatment of androgenetic alopecia in Thai men and women: a 24-week, randomized, double-blind, sham device-controlled trial. 61
30569416 2019
190
Shedding light on the FDA's 510(k) approvals process: low-level laser therapy devices used in the treatment of androgenetic alopecia. 61
30252550 2019
191
The rise of transcutaneous drug delivery for the management of alopecia: a review of existing literature and an eye towards the future. 61
30300013 2019
192
Distinguishing Lipedematous Scalp, Lipedematous Alopecia, and Diffuse Alopecia Areata. 61
31559257 2019
193
Erosive pustular dermatosis of the scalp: A neutrophilic folliculitis within the spectrum of neutrophilic dermatoses: A clinicopathologic study of 30 cases. 61
30617027 2019
194
Post-Finasteride Syndrome: An Induced Delusional Disorder with the Potential of a Mass Psychogenic Illness? 61
31559258 2019
195
Generation of an integration-free human induced pluripotent stem cell line MUSIi010-A from occipital scalp fibroblasts of a male patient with androgenetic alopecia. 61
31228683 2019
196
Letter in response to "The effectiveness of adding low-level light therapy to minoxidil 5% solution in the treatment of patients with androgenetic alopecia". 61
30880717 2019
197
Finasteride for androgenetic alopecia is not associated with sexual dysfunction: a survey-based, single-centre, controlled study. 61
30835851 2019
198
Photographic assessment improves adherence to recommended follow-up in patients with androgenetic alopecia and alopecia areata: A retrospective cohort study. 61
31062723 2019
199
Long-term treatment with finasteride induces apoptosis and pathological changes in female mice. 61
30943778 2019
200
Quality of Life Assessment in Patients with Androgenetic Alopecia. 61
31523105 2019
201
A small dose of botulinum toxin A is effective for treating androgenetic alopecia in Chinese patients. 61
30566260 2019
202
Female Pattern Hair Loss and Androgen Excess: A Report From the Multidisciplinary Androgen Excess and PCOS Committee. 61
30785992 2019
203
Finasteride Enhances Stem Cell Signals of Human Dermal Papilla Cells. 61
31280211 2019
204
Biofibre® artificial hair implant: Retrospective study on 1,518 patients with alopecia and present role in hair surgery. 61
31168904 2019
205
Histopathology of aging of the hair follicle. 61
30932205 2019
206
Adipose Infiltration of the Dermis, Involving the Arrector Pili Muscle, and Dermal Displacement of Eccrine Sweat Coils: New Histologic Observations in Frontal Fibrosing Alopecia. 61
30624243 2019
207
Progressive expression of PPARGC1α is associated with hair miniaturization in androgenetic alopecia. 61
31217429 2019
208
Fibrosing Alopecia in a Pattern Distribution (FAPD) in 16 African-Descent and Hispanic Female Patients: A Challenging Diagnosis. 61
31367598 2019
209
Harvested vs estimated follicular units in hair transplantation. 61
30084223 2019
210
Tretinoin enhances minoxidil response in androgenetic alopecia patients by upregulating follicular sulfotransferase enzymes. 61
30974011 2019
211
Finasteride and Erectile Dysfunction in Patients with Benign Prostatic Hyperplasia or Male Androgenetic Alopecia. 61
30209896 2019
212
Correlation of Trichoscopic Findings in Androgenetic Alopecia and the Disease Severity. 61
31360040 2019
213
A semiquantitative grading scale for frontal and vertex of androgenetic alopecia. 61
30592306 2019
214
Vitamin D and the Skin: A Review for Dermatologists. 61
30857638 2019
215
Premature Desquamation of the Inner Root Sheath in Noninflamed Hair Follicles as a Specific Marker for Central Centrifugal Cicatricial Alopecia. 61
30562220 2019
216
Platelet rich plasma in androgenetic alopecia: A systematic review. 61
30667146 2019
217
Prostaglandins in androgenetic alopecia in 12 men and four female. 61
30730082 2019
218
Expert consensus on the management of Androgenetic Alopecia in India. 61
31360037 2019
219
Identification of the sulfotransferase iso-enzyme primarily responsible for the bio-activation of topical minoxidil. 61
31184104 2019
220
Faster calculation of scalp area in androgenetic alopecia before Platelet Rich Plasma therapy using a mobile application imagemeterTM. 61
31153948 2019
221
Familial frontal fibrosing alopecia: A cross-sectional study of 20 cases from nine families. 61
30430555 2019
222
The Trichoscopy Derived Sinclair Scale: Enhancing visual assessment through quantitative trichoscopy. 61
30565210 2019
223
Bold to do - bald to be? Outcomes decades after harvesting the scalp in burned children. 61
30337156 2019
224
Finasteride-Induced Inhibition of 5α-Reductase Type 2 Could Lead to Kidney Damage-Animal, Experimental Study. 61
31100850 2019
225
The Higher Number and Longer Duration of Kenogen Hairs Are the Main Cause of the Hair Rarefaction in Androgenetic Alopecia. 61
31049336 2019
226
Platelet-Rich Plasma and Micrografts Enriched with Autologous Human Follicle Mesenchymal Stem Cells Improve Hair Re-Growth in Androgenetic Alopecia. Biomolecular Pathway Analysis and Clinical Evaluation. 61
30965624 2019
227
What's New in Hair Loss. 61
30850035 2019
228
Acne development in male androgenetic alopecia. 61
30499125 2019
229
Platelet rich plasma for the management of hair loss: Better alone or in combination? 61
29904992 2019
230
Off-Label Use of Topical Minoxidil in Alopecia: A Review. 61
30604379 2019
231
The Efficacy of Platelet-Rich Plasma in the Field of Hair Restoration and Facial Aesthetics-A Systematic Review and Meta-analysis. 61
30606055 2019
232
Efficacy of Off-Label Topical Treatments for the Management of Androgenetic Alopecia: A Review. 61
30652260 2019
233
Controversies in the treatment of androgenetic alopecia: The history of finasteride. 61
30253001 2019
234
New drugs under investigation for the treatment of alopecias. 61
30642204 2019
235
Treatment of male pattern alopecia with platelet-rich plasma: A double-blind controlled study with analysis of platelet number and growth factor levels. 61
30287324 2019
236
HrQoL in hair loss-affected patients with alopecia areata, androgenetic alopecia and telogen effluvium: the role of personality traits and psychosocial anxiety. 61
30394586 2019
237
A Study to Compare the Efficacy of Platelet-rich Plasma and Minoxidil Therapy for the Treatment of Androgenetic Alopecia. 61
31007475 2019
238
Evaluating hair growth promoting effects of candidate substance: A review of research methods. 61
30904351 2019
239
The role of photobiomodulation when associated with microneedling in female pattern hair loss: A randomized, double blind, parallel group, three arm, clinical study protocol. 61
30896659 2019
240
Evaluation of long-term efficacy of finasteride in Korean men with androgenetic alopecia using the basic and specific classification system. 61
30536893 2019
241
Efficacy and safety of a new 5% minoxidil formulation in male androgenetic alopecia: A randomized, placebo-controlled, double-blind, noninferiority study. 61
29659116 2019
242
Laser-assisted drug delivery for the treatment of androgenetic alopecia: ablative laser fractional photothermolysis to enhance cutaneous topical delivery of platelet-rich plasma - with or without concurrent bimatoprost and/or minoxidil. 61
30865404 2019
243
Dickkopf-1 Expression in Androgenetic Alopecia and Alopecia Areata in Male Patients. 61
30640755 2019
244
Platelet-rich plasma for androgenetic alopecia: A review of the literature and proposed treatment protocol. 61
30809579 2019
245
Platelet-rich plasma on female androgenetic alopecia: Tested on 10 patients. 61
29707872 2019
246
Methods of treatment patients with androgenetic alopecia based on reference of Department of Dermatology in Cracow. 61
30830894 2019
247
Serum biotin and zinc in male androgenetic alopecia. 61
30714301 2019
248
The Efficacy of Topical Minoxidil for Non-Scarring Alopecia: A Systematic Review 61
30794366 2019
249
Cortexolone 17α-Propionate (Clascoterone) is an Androgen Receptor Antagonist in Dermal Papilla Cells In Vitro 61
30811143 2019
250
Review of Human Hair Follicle Biology: Dynamics of Niches and Stem Cell Regulation for Possible Therapeutic Hair Stimulation for Plastic Surgeons. 61
30324295 2019
251
Microbiome in the hair follicle of androgenetic alopecia patients. 61
31050675 2019
252
Menopausal Acne - Challenges And Solutions. 61
31754313 2019
253
Metabolic Syndrome and Skin Diseases. 61
31824416 2019
254
Genetic variations associated with response to dutasteride in the treatment of male subjects with androgenetic alopecia. 61
31525235 2019
255
Minoxidil and its use in hair disorders: a review. 61
31496654 2019
256
The efficacy and safety of dutasteride compared with finasteride in treating men with androgenetic alopecia: a systematic review and meta-analysis. 61
30863034 2019
257
The effect of GGC and CAG repeat polymorphisms on the androgen receptor gene in response to finasteride therapy in men with androgenetic alopecia. 61
31949455 2019
258
Adverse Sexual Effects of Treatment with Finasteride or Dutasteride for Male Androgenetic Alopecia: A Systematic Review and Meta-analysis. 61
30206635 2019
259
The Association of Metabolic Syndrome and Insulin Resistance in Early-Onset Androgenetic Alopecia in Males: A Case-Control Study. 61
30745631 2019
260
Insights into Male Androgenetic Alopecia: Differential Gene Expression Profiling of Plucked Hair Follicles and Integration with Genetic Data. 61
30009830 2019
261
Meta-Analysis on the Efficacy and Safety of Traditional Chinese Medicine as Adjuvant Therapy for Refractory Androgenetic Alopecia. 61
31781285 2019
262
Telogen effluvium: a comprehensive review. 61
31686886 2019
263
Jagged1 and Epidermal Growth Factor Promoted Androgen-Suppressed Mouse Hair Growth In Vitro and In Vivo. 61
32082154 2019
264
Erosive pustular dermatosis of the scalp: challenges and solutions. 61
31571969 2019
265
Correlation between Clinical Features, Biochemical Parameters, and Histopathological Findings in Women with Patterned Baldness: A Study from North India. 61
31057268 2019
266
Treatment of male rats with finasteride, an inhibitor of 5alpha-reductase enzyme, induces long-lasting effects on depressive-like behavior, hippocampal neurogenesis, neuroinflammation and gut microbiota composition. 61
30265917 2019
267
Autistic-Undisciplined Thinking in the Practice of Medical Trichology. 61
30820126 2019
268
A Study of the Histopathological Features of Alopecias on Transverse Sections of Scalp Biopsies. 61
30745635 2019
269
Platelet-rich plasma and microneedling improves hair growth in patients ofandrogenetic alopecia when used as an adjuvant to minoxidil. 61
30693667 2019
270
Feature characterization of scarring and non-scarring types of alopecia by multiphoton microscopy. 61
30248187 2019
271
Assessment of Safe Donor Zone of Scalp and Beard for Follicular Unit Extraction in Indian Men: A Study of 580 Cases. 61
31057266 2019
272
Dermoscopic pre- and posttreatment evaluation in patients with androgenetic alopecia on platelet-rich plasma-A prospective study. 61
30556270 2018
273
The new paradigm for androgenetic alopecia and plant-based folk remedies: 5α-reductase inhibition, reversal of secondary microinflammation and improving insulin resistance. 61
30195058 2018
274
Over-the-Counter Hair Loss Treatments: Help or Hype? 61
30586264 2018
275
A randomized, double-blind controlled study of the efficacy and safety of topical solution of 0.25% finasteride admixed with 3% minoxidil vs. 3% minoxidil solution in the treatment of male androgenetic alopecia. 61
29972712 2018
276
The relation between androgenetic thin hair diagnosed by trichoscope and benign prostatic hyperplasia. 61
30520225 2018
277
The relationship between self-esteem and hair transplantation satisfaction in male androgenetic alopecia patients. 61
30582267 2018
278
Efficacy of non-surgical treatments for androgenetic alopecia: a systematic review and network meta-analysis. 61
29797431 2018
279
Association of Hair Loss With Health Utility Measurements Before and After Hair Transplant Surgery in Men and Women. 61
30242313 2018
280
Development and evaluation of finasteride loaded ethosomes for targeting to the pilosebaceous unit. 61
29087225 2018
281
Study of the efficacy of carboxytherapy in alopecia. 61
29460509 2018
282
Low-dose daily aspirin reduces topical minoxidil efficacy in androgenetic alopecia patients. 61
30226287 2018
283
Fractional non-ablative laser-assisted drug delivery leads to improvement in male and female pattern hair loss. 61
29452017 2018
284
Efficacy and Safety of a Low-Level Light Therapy for Androgenetic Alopecia: A 24-Week, Randomized, Double-Blind, Self-Comparison, Sham Device-Controlled Trial. 61
29957664 2018
285
A Randomized Controlled, Single-Observer Blinded Study to Determine the Efficacy of Topical Minoxidil plus Microneedling versus Topical Minoxidil Alone in the Treatment of Androgenetic Alopecia. 61
30886475 2018
286
Efficacy of 1,550-nm Erbium-Glass Fractional Laser Treatment and Its Effect on the Expression of Insulin-Like Growth Factor 1 and Wnt/β-Catenin in Androgenetic Alopecia. 61
30096107 2018
287
White and yellow dots as new trichoscopic signs of severe female androgenetic alopecia in dark skin phototypes. 61
30043983 2018
288
Evaluation of the Expression of Genes Associated with Inflammation and Apoptosis in Androgenetic Alopecia by Targeted RNA-Seq. 61
30410894 2018
289
Serum androgens and prostate-specific antigen levels in androgenetic alopecia: is there a difference between frontal and vertex baldness? 61
29237093 2018
290
Use of Minoxidil Sulfate versus Minoxidil Base in Androgenetic Alopecia Treatment: Friend or Foe? 61
30410915 2018
291
Systematic review of platelet-rich plasma (PRP) preparation and composition for the treatment of androgenetic alopecia. 61
29790267 2018
292
Injectable Platelet-, Leukocyte-, and Fibrin-Rich Plasma (iL-PRF) in the Management of Androgenetic Alopecia. 61
30045107 2018
293
Comparison of quality of life in patients with androgenetic alopecia and alopecia areata. 61
30156613 2018
294
Synergistic effect of platelet-rich plasma injections and scalp lifting in androgenetic alopecia. 61
30217282 2018
295
Minoxidil in the treatment of androgenetic alopecia. 61
30155952 2018
296
The effectiveness of adding low-level light therapy to minoxidil 5% solution in the treatment of patients with androgenetic alopecia. 61
30027912 2018
297
Bayesian measurement-error-driven hidden Markov regression model for calibrating the effect of covariates on multistate outcomes: Application to androgenetic alopecia. 61
29785802 2018
298
Evaluating the Efficacy of Different Platelet-Rich Plasma Regimens for Management of Androgenetic Alopecia: A Single-Center, Blinded, Randomized Clinical Trial. 61
30141776 2018
299
Estimation of Zinc and Iron Levels in the Serum and Hair of Women with Androgenetic Alopecia: Case-control Study. 61
30210156 2018
300
Translation into Portuguese language (Brazil), transcultural adaptation and validation of the quality of life questionnaire in female pattern hair loss (WAA-QoL-BP). 61
30156620 2018
301
Guidelines for the diagnosis and treatment of male-pattern and female-pattern hair loss, 2017 version. 61
29863806 2018
302
A bald statement - Current approaches to manipulate miniaturisation focus only on promoting hair growth. 61
29787625 2018
303
Stem cell therapy as a novel therapeutic intervention for resistant cases of alopecia areata and androgenetic alopecia. 61
27553744 2018
304
Efficacy and Safety of a Topical Botanical in Female Androgenetic Alopecia: A Randomized, Single-Blinded, Vehicle-Controlled Study. 61
30197894 2018
305
Automated digital image analysis (TrichoScan) in male patients with androgenetic alopecia; comparison with manual marking of hairs on trichoscopic images. 61
29363174 2018
306
Alopecia Areata is Associated with Increased Expression of Heart Disease Biomarker Cardiac Troponin I. 61
29740659 2018
307
Psychological assessment in 355 Chinese college students with androgenetic alopecia. 61
30075498 2018
308
Post-finasteride syndrome and post-SSRI sexual dysfunction: two sides of the same coin? 61
29675596 2018
309
Nonmalignant late cutaneous changes after allogeneic hematopoietic stem cell transplant in children. 61
29588248 2018
310
Perception of Hair Loss and Education Increases the Treatment Willingness in Patients With Androgenetic Alopecica: A Population-Based Study. 61
30065579 2018
311
Androgen modulation of Wnt/β-catenin signaling in androgenetic alopecia. 61
29549490 2018
312
New Perspectives on the Treatment of Androgenetic Alopecia. 61
29801692 2018
313
Androgenetic Alopecia Treatment in Asian Men. 61
30057663 2018
314
Prospective randomized study of sexual function in men taking dutasteride for the treatment of androgenetic alopecia. 61
29667763 2018
315
Impact on Quality of Life in Patients who came with Androgenetic Alopecia for Hair Transplantion Surgery in a Clinic. 61
30387465 2018
316
Introducing Platelet-Rich Stroma: Platelet-Rich Plasma (PRP) and Stromal Vascular Fraction (SVF) Combined for the Treatment of Androgenetic Alopecia. 61
29554209 2018
317
Prescribing Habits for Androgenic Alopecia Among Dermatologists in Spain in 2017: A Cross-Sectional Study. 61
29656764 2018
318
Medical comorbidities in patients with lichen planopilaris, a retrospective case-control study. 61
29682736 2018
319
Persistent Alopecia in a Breast Cancer Patient Following Taxane Chemotherapy and Adjuvant Endocrine Therapy: Case Report and Review of Post-treatment Hair Loss in Oncology Patients with Breast Cancer. 61
30280054 2018
320
Interconnected PolymerS TeChnology (IPSTiC): An Effective Approach for the Modulation of 5α-Reductase Activity in Hair Loss Conditions. 61
30002324 2018
321
Photobiomodulation therapy for androgenetic alopecia: A clinician's guide to home-use devices cleared by the Federal Drug Administration. 61
29020478 2018
322
Original article: Platelet-rich plasma with microneedling in androgenetic alopecia along with dermoscopic pre- and post-treatment evaluation. 61
28771982 2018
323
A proprietary herbal extract against hair loss in androgenetic alopecia and telogen effluvium: a placebo-controlled, single-blind, clinical-instrumental study. 61
29945259 2018
324
Is there a pathogenetic link between frontal fibrosing alopecia, androgenetic alopecia and fibrosing alopecia in a pattern distribution? 61
29224248 2018
325
Recycling of Previously Transplanted Hair: A Novel Indication for Follicular Unit Extraction. 61
29983809 2018
326
Drug Treatment for Androgenetic Alopecia: First Italian Questionnaire Survey on What Dermatologists Think about Finasteride. 61
29574572 2018
327
Quality of Life with Alopecia Areata versus Androgenetic Alopecia Assessed Using Hair Specific Skindex-29. 61
29853767 2018
328
Letter to the Editor: androgenetic alopecia; drug safety and therapeutic strategies. 61
29707969 2018
329
Response to the letter to the editor; Androgenetic alopecia; drug safety and therapeutic strategies. 61
29707983 2018
330
Digit ratio 2D:4D is a possible indicator for androgenetic alopecia in males. 61
28856798 2018
331
Mechanical forces in skin disorders. 61
29567352 2018
332
Transcutaneous implantation of valproic acid-encapsulated dissolving microneedles induces hair regrowth. 61
29554482 2018
333
Validation of a Cross-cultural Adaptation of the Hair Specific Skindex-29 Scale to Spanish. 61
29548490 2018
334
Endocrine Therapy-Induced Alopecia in Patients With Breast Cancer. 61
29641806 2018
335
Genetic and molecular aspects of androgenetic alopecia. 61
29595184 2018
336
[Injection of PRP (Platelet-rich plasma) as a treatment for androgenetic alopecia : a systematic review of the literature]. 61
29869472 2018
337
Minoxidil Downregulates Interleukin-1 Alpha Gene Expression in HaCaT Cells. 61
30034189 2018
338
Determination of finasteride and its metabolite in urine by dispersive liquid-liquid microextraction combined with field-enhanced sample stacking and sweeping. 61
29534820 2018
339
Preservation of stem cells in androgenetic alopecia. 61
29055061 2018
340
Androgenetic alopecia; drug safety and therapeutic strategies. 61
29363345 2018
341
Identification of Functional Patterns of Androgenetic Alopecia Using Transcriptome Profiling in Distinct Locations of Hair Follicles. 61
29122575 2018
342
A Systematic Review of Topical Finasteride in the Treatment of Androgenetic Alopecia in Men and Women. 61
29601622 2018
343
Medical Comorbidities and the Onset of Androgenetic Alopecia: A Population-Based, Case-Control Study. 61
29606834 2018
344
Proprietary Herbal Extract Downregulates the Gene Expression of IL-1α in HaCaT Cells: Possible Implications Against Nonscarring Alopecia. 61
30302033 2018
345
Microneedling for the treatment of hair loss? 61
29194786 2018
346
Androgens and androgen receptor action in skin and hair follicles. 61
28912032 2018
347
Efficacy of a cosmetic phyto-caffeine shampoo in female androgenetic alopecia. 61
29512972 2018
348
A preliminary study on topical cetirizine in the therapeutic management of androgenetic alopecia. 61
28604133 2018
349
The tendency towards the development of psychosexual disorders in androgenetic alopecia according to the different stages of hair loss: a cross-sectional study. 61
29723381 2018
350
Association of Androgenetic Alopecia with Metabolic Syndrome: A Case-control Study on 100 Patients in a Tertiary Care Hospital in South India. 61
29911030 2018
351
Hair and nail diseases in the mature patient. 61
29566920 2018
352
Case Report of Connubial Frontal Fibrosing Alopecia. 61
29769781 2018
353
Graft versus Host Disease Presenting as Fibrosing Alopecia in a Pattern Distribution: A Model for Pathophysiological Understanding of Cicatricial Pattern Hair Loss. 61
29769782 2018
354
Variation in male sex hormone levels among the pattern subtypes of hair loss in patients with androgenetic alopecia. 61
28266054 2018
355
Gender-specific risk factors for androgenetic alopecia in the Korean general population: Associations with medical comorbidities and general health behaviors. 61
29330930 2018
356
The clinical effect of JetpPeel-assisted topical minoxidil in the treatment of androgenetic alopecia: A randomized pilot study. 61
29166130 2018
357
The use of minoxidil in the treatment of male and female androgenetic alopecia: a story of more than 30 years. 61
29319278 2018
358
Prostaglandin D2-Mediated DP2 and AKT Signal Regulate the Activation of Androgen Receptors in Human Dermal Papilla Cells. 61
29439547 2018
359
Establishment and characterization of five immortalized human scalp dermal papilla cell lines. 61
29331373 2018
360
Comparison of the Efficacy of Homologous and Autologous Platelet-Rich Plasma (PRP) for Treating Androgenic Alopecia. 61
29101437 2018
361
Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men - short version. 61
29178529 2018
362
Automatic Artificial Hair Implant: Safety and Efficacy in Androgenetic Alopecia. A Prospective Study with a Highly Biocompatible Fiber. 61
29483977 2018
363
Double-Blind, Placebo-Controlled Pilot Study on the Use of Platelet-Rich Plasma in Women With Female Androgenetic Alopecia. 61
28562436 2018
364
Early-onset baldness and the risk of aggressive prostate cancer: findings from a case-control study. 61
29139043 2018
365
Emotional Consequences of Finasteride: Fool's Gold. 61
26868914 2018
366
Platelet-Rich Plasma in Combination With 5% Minoxidil Topical Solution and 1 mg Oral Finasteride for the Treatment of Androgenetic Alopecia: A Randomized Placebo-Controlled, Double-Blind, Half-Head Study. 61
28562433 2018
367
Effectiveness of Platelet-Rich Plasma for Androgenetic Alopecia: A Review of the Literature. 61
29457005 2018
368
A Meta-analysis On Evidence Of Platelet-rich Plasma for Androgenetic Alopecia. 61
29440850 2018
369
Utility of Horizontal Sections of Scalp Biopsies in Differentiating between Androgenetic Alopecia and Alopecia Areata. 61
30092597 2018
370
Mediterranean diet: fresh herbs and fresh vegetables decrease the risk of Androgenetic Alopecia in males. 61
29181579 2018
371
Finasteride nano-transferosomal gel formula for management of androgenetic alopecia: ex vivo investigational approach. 61
30104862 2018
372
Mechanical and Controlled PRP Injections in Patients Affected by Androgenetic Alopecia. 61
29443105 2018
373
Finasteride Topical Delivery Systems for Androgenetic Alopecia. 61
29366416 2018
374
Microneedling: Where do we stand now? A systematic review of the literature. 61
28690124 2018
375
Non-scarring Alopecias in Iranian Patients: A Histopathological Study With Hair Counts. 61
30636954 2018
376
Minoxidil-encapsulated poly(L-lactide-co-glycolide) nanoparticles with hair follicle delivery properties prepared using W/O/W solvent evaporation and sonication. 61
29457595 2018
377
Does a male polycystic ovarian syndrome equivalent exist? 61
28711970 2018
378
Clinical Outcome and Safety Profile of Patients Underwent Hair Transplantation Surgery by Follicular Unit Extraction. 61
30058640 2018
379
Alopecia and the metabolic syndrome. 61
29241753 2018
380
The promotion of hair regrowth by topical application of a Perilla frutescens extract through increased cell viability and antagonism of testosterone and dihydrotestosterone. 61
28905175 2018
381
The role of oxidative stress in early-onset androgenetic alopecia. 61
27987270 2017
382
[What is the value of low-energie lasers in the treatment of androgenetic alopecia ?] 61
29271134 2017
383
Hair loss at injection sites of mesotherapy for alopecia. 61
28160387 2017
384
Long-term efficacy and safety of the dual 5-alpha reductase blocker dutasteride on male androgenetic alopecia patients. 61
27988928 2017
385
Change in Prostate Specific Antigen Concentration in Men with Prostate Specific Antigen Less than 2.5 ng/ml Taking Low Dose Finasteride or Dutasteride for Male Androgenetic Alopecia. 61
28743526 2017
386
Minoxidil Acts as an Antiandrogen: A Study of 5α-reductase Type 2 Gene Expression in a Human Keratinocyte Cell Line. 61
30064598 2017
387
Effect of Ficus carica leaf extract on the gene expression of selected factors in HaCaT cells. 61
28432719 2017
388
Enhancing hair growth in male androgenetic alopecia by a combination of fractional CO2 laser therapy and hair growth factors. 61
28528395 2017
389
Platelet-rich Plasma by Single Spin Process in Male Pattern Androgenetic Alopecia: Is it an Effective Treatment? 61
29204389 2017
390
Platelet-rich Plasma by Single-spin Process in Male Pattern Androgenetic Alopecia: Is it an Effective Treatment? 61
29204390 2017
391
Study of gene expression alteration in male androgenetic alopecia: evidence of predominant molecular signalling pathways. 61
28403520 2017
392
Topical cetirizine 1% for treatment of androgenetic alopecia. 61
28796428 2017
393
Regulatory pathways implicated in male androgenetic alopecia pathogenesis. 61
29192995 2017
394
Low plasma zinc levels in androgenetic alopecia. 61
28566562 2017
395
Platelet rich plasma for treatment of non-scarring hair loss: systematic review of literature. 61
28271918 2017
396
In Vitro and In Vivo Skin Distribution of 5α-Reductase Inhibitors Loaded Into Liquid Crystalline Nanoparticles. 61
28652158 2017
397
Sexual side effects of 5-α-reductase inhibitors finasteride and dutasteride: A comprehensive review. 61
29447628 2017
398
New Insight Into the Pathophysiology of Hair Loss Trigger a Paradigm Shift in the Treatment Approach. 61
29141068 2017
399
GWAS for male-pattern baldness identifies 71 susceptibility loci explaining 38% of the risk. 61
29146897 2017
400
Dermatologic manifestations of endocrine disorders. 61
29184811 2017
401
Therapeutic experience with oral finasteride for androgenetic alopecia in female-to-male transgender patients. 61
28691187 2017
402
A Proposal of an Effective Platelet-rich Plasma Protocol for the Treatment of Androgenetic Alopecia. 61
29118521 2017
403
Social selection favours offspring prone to the development of androgenetic alopecia. 61
29254307 2017
404
Mechanism of action of minoxidil in the treatment of androgenetic alopecia is likely mediated by mitochondrial adenosine triphosphate synthase-induced stem cell differentiation. 61
29254313 2017
405
Exogen Hairs in Women with and without Hair Loss. 61
29177147 2017
406
Knockout of p16INK4a promotes aggregative growth of dermal papilla cells. 61
29267490 2017
407
Yellow dots in trichoscopy: relevance, clinical significance and peculiarities. 61
29166518 2017
408
Eccrine Duct Dilation as a Marker of Cicatricial Alopecia. 61
27673387 2017
409
Platelet-rich plasma for androgenetic alopecia: Does it work? Evidence from meta analysis. 61
28296142 2017
410
Hair Loss: Common Causes and Treatment. 61
28925637 2017
411
Hair Transplantation in Migraine Headache Patients. 61
29062667 2017
412
Genome-wide gene expression dataset used to identify potential therapeutic targets in androgenetic alopecia. 61
28589172 2017
413
The combination of overweight and smoking increases the severity of androgenetic alopecia. 61
28555720 2017
414
The Association between Exercise and Androgenetic Alopecia: A Survey-Based Study. 61
28761311 2017
415
Understanding patient and physician perceptions of male androgenetic alopecia treatments in Asia-Pacific and Latin America. 61
28370105 2017
416
Glycolipid and Hormonal Profiles in Young Men with Early-Onset Androgenetic Alopecia: A meta-analysis. 61
28798373 2017
417
Experimental and early investigational drugs for androgenetic alopecia. 61
28689433 2017
418
Genomewide differential expression profiling of long non-coding RNAs in androgenetic alopecia in a Chinese male population. 61
28419572 2017
419
Oxidative stress management in the hair follicle: Could targeting NRF2 counter age-related hair disorders and beyond? 61
28685843 2017
420
A genomic approach to susceptibility and pathogenesis leads to identifying potential novel therapeutic targets in androgenetic alopecia. 61
28263792 2017
421
Prevalence of fronto-vertex baldness and its association with family history of androgenetic alopecia in Korean men using basic and specific classification. 61
27599903 2017
422
Extensive Donor Site Keloids in Follicular Unit Extraction Hair Transplantation. 61
28932067 2017
423
Efficacy of topical caffeine in male androgenetic alopecia. 61
28677188 2017
424
Androgenetic alopecia: a review. 61
28349362 2017
425
The effectiveness of treatments for androgenetic alopecia: A systematic review and meta-analysis. 61
28396101 2017
426
A Pilot Study to Evaluate Effectiveness of Botulinum Toxin in Treatment of Androgenetic Alopecia in Males. 61
29403190 2017
427
Mesotherapy with Dutasteride in the Treatment of Androgenetic Alopecia. 61
28932074 2017
428
Dyslipidemia in patients with androgenetic alopecia. Statins, finasteride or both? 61
28621499 2017
429
Lipid profile in patients with androgenetic alopecia: a meta-analysis. 61
27717019 2017
430
Higher plasma leptin is associated with higher risk of androgenetic alopecia in men. 61
28423238 2017
431
Adipocyte-myofibroblast transition as a possible pathophysiological step in androgenetic alopecia. 61
28482134 2017
432
Novel Approach to Treating Androgenetic Alopecia in Females With Photobiomodulation (Low-Level Laser Therapy). 61
28328705 2017
433
Infundibular protein and RNA microarray analyses from affected and clinically non-affected scalp in male androgenetic alopecia patients. 61
28266729 2017
434
Genetics and other factors in the aetiology of female pattern hair loss. 61
28453904 2017
435
Erosive pustular dermatosis of the scalp: Clinical, trichoscopic, and histopathologic features of 20 cases. 61
28214042 2017
436
A study of the efficacy of platelet-rich plasma in the treatment of androgenetic alopecia in males. 61
27679404 2017
437
Retrospective Assessment of Follicular Unit Density in Asian Men With Androgenetic Alopecia. 61
28362669 2017
438
The Effect of Plasma Rich in Growth Factors on Pattern Hair Loss: A Pilot Study. 61
28221183 2017
439
Body to Scalp: Evolving Trends in Body Hair Transplantation. 61
28584752 2017
440
Hair growth promoting effect of white wax and policosanol from white wax on the mouse model of testosterone-induced hair loss. 61
28249244 2017
441
Bimatoprost for the treatment of eyelash, eyebrow and scalp alopecia. 61
28264599 2017
442
The evolution of artificial hair implantation. 61
28702978 2017
443
DERMAL ADIPOSE TISSUE IN HAIR FOLLICLE CYCLING: POSSIBLE APPLICATIONS IN ALOPECIA? 61
28574382 2017
444
Adult Onset Hair Casts: Nits Which Do Not Itch! 61
28839391 2017
445
New Treatments for Hair Loss. 61
28061966 2017
446
Skin Manifestations of Insulin Resistance: From a Biochemical Stance to a Clinical Diagnosis and Management. 61
27921251 2017
447
Meta-analysis of efficacy of platelet-rich plasma therapy for androgenetic alopecia. 61
27152474 2017
448
An Open-Label Evaluator Blinded Study of the Efficacy and Safety of a New Nutritional Supplement in Androgenetic Alopecia: A Pilot Study. 61
28367262 2017
449
A Critical Assessment of the Evidence for Low-Level Laser Therapy in the Treatment of Hair Loss. 61
27618394 2017
450
Evaluation of Not-Activated and Activated PRP in Hair Loss Treatment: Role of Growth Factor and Cytokine Concentrations Obtained by Different Collection Systems. 61
28216604 2017
451
An Open-Label Randomized Multicenter Study Assessing the Noninferiority of a Caffeine-Based Topical Liquid 0.2% versus Minoxidil 5% Solution in Male Androgenetic Alopecia. 61
29055953 2017
452
A Comparative Study of Microneedling with Platelet-rich Plasma Plus Topical Minoxidil (5%) and Topical Minoxidil (5%) Alone in Androgenetic Alopecia. 61
28761259 2017
453
Superiority of dutasteride over finasteride in hair regrowth and reversal of miniaturization in men with androgenetic alopecia: A randomized controlled open-label, evaluator-blinded study. 61
27549867 2017
454
Androgens modify Wnt agonists/antagonists expression balance in dermal papilla cells preventing hair follicle stem cell differentiation in androgenetic alopecia. 61
27769713 2017
455
Hair growth effect of traditional Chinese medicine BeauTop on androgenetic alopecia patients: A randomized double-blind placebo-controlled clinical trial. 61
28123489 2017
456
Quality of life assessment in patients with alopecia areata and androgenetic alopecia in the People's Republic of China. 61
28203058 2017
457
Stem cells from human hair follicles: first mechanical isolation for immediate autologous clinical use in androgenetic alopecia and hair loss. 61
28725654 2017
458
[Mesotherapy in trichology]. 61
28722459 2017
459
An analysis of gene expression data involving examination of signaling pathways activation reveals new insights into the mechanism of action of minoxidil topical foam in men with androgenetic alopecia. 61
28594262 2017
460
Comparative transcriptome profiling provides new insights into mechanisms of androgenetic alopecia progression. 61
27239811 2017
461
Bioactives in Chinese Proprietary Medicine Modulates 5α-Reductase Activity and Gene Expression Associated with Androgenetic Alopecia. 61
28450835 2017
462
[Typical androgenetic alopecia?] 61
27837206 2017
463
[Androgenetic alopecia in women]. 61
28722458 2017
464
A Case Report of Cushing's Disease Presenting as Hair Loss. 61
28413388 2017
465
Frequency, severity and related factors of androgenetic alopecia in dermatology outpatient clinic: hospital-based cross-sectional study in Turkey. 61
28225954 2017
466
Low-level laser therapy as a treatment for androgenetic alopecia. 61
27114071 2017
467
Dutasteride in Androgenetic Alopecia: An Update. 61
28294070 2017
468
Design of Finasteride-Loaded Nanoparticles for Potential Treatment of Alopecia. 61
28689207 2017
469
A Comparative Study between the Efficacy and Safety of 5% Minoxidil Solution and 5% Minoxidil Milky Lotion in the Treatment of Male Androgenic Alopecia. 61
29911772 2017
470
A Practical Approach to the Diagnosis and Management of Hair Loss in Children and Adolescents. 61
28791288 2017
471
Alopecia and platelet-derived therapies. 61
29270414 2017
472
Negative Impact of Testosterone Deficiency and 5α-Reductase Inhibitors Therapy on Metabolic and Sexual Function in Men. 61
29224108 2017
473
Treatment of chronic telogen effluvium with oral minoxidil: A retrospective study. 61
29167734 2017
474
Perception of Hair Transplant for Androgenetic Alopecia. 61
27560098 2016
475
Clinical and Biochemical Characteristics in PCOS Women With Menstrual Abnormalities. 61
28546817 2016
476
Assessment of vitamin D receptors in alopecia areata and androgenetic alopecia. 61
27151518 2016
477
A Mechanistic Model of Platelet-Rich Plasma Treatment for Androgenetic Alopecia. 61
27631460 2016
478
[Androgenetic alopecia: What's new in the last two years ?] 61
27814891 2016
479
Frontal Fibrosing Alopecia in Men: Presentations in 12 Cases and a Review of the Literature. 61
27499250 2016
480
Topical application of the Wnt/β-catenin activator methyl vanillate increases hair count and hair mass index in women with androgenetic alopecia. 61
27121450 2016
481
Dermoscopy in General Dermatology: A Practical Overview. 61
27613297 2016
482
A 6-month, randomized, double-blind, placebo-controlled study evaluating the ability of a marine complex supplement to promote hair growth in men with thinning hair. 61
27506633 2016
483
Efficacy of platelet-rich plasma in the treatment of androgenetic (male-patterned) alopecia: A pilot randomized controlled trial. 61
27593381 2016
484
Effects of flavonoid derivatives on human microvascular endothelial cells. 61
26936689 2016
485
Double-Blind, Placebo-Controlled Pilot Study on the Use of Platelet-Rich Plasma in Women With Female Androgenetic Alopecia. 61
27608205 2016
486
Adverse Effects of 5-Alpha Reductase Inhibitor Therapy in Men With Androgenetic Alopecia: Is There Cause for Concern? 61
27436801 2016
487
Relationship between androgenetic alopecia and cardiovascular risk factors according to BASP classification in Koreans. 61
27028221 2016
488
Analysis of androgenetic alopecia in Amerindian people (Mapuche) from southern Chile. 61
27459731 2016
489
Asymmetry of the Receding Hairline in Men With Early Androgenetic Alopecia. 61
27421295 2016
490
Multi-therapies in androgenetic alopecia: review and clinical experiences. 61
27424565 2016
491
Relevance of trichoscopy in the differential diagnosis of alopecia: A cross-sectional study from North India. 61
27297280 2016
492
A New Subtype of Lichen Planopilaris Affecting Vellus Hairs and Clinically Mimicking Androgenetic Alopecia. 61
27661430 2016
493
Commentary on A New Subtype of Lichen Planopilaris Affecting Vellus Hairs and Clinically Mimicking Androgenetic Alopecia. 61
27661431 2016
494
Relation of urinary stone disease with androgenetic alopecia and serum testosterone levels. 61
27155830 2016
495
Hair diseases: a big problem on a small surface. 61
27881935 2016
496
Association of metabolic syndrome with female pattern hair loss in women: A case-control study. 61
27060965 2016
497
Long-term safety and efficacy of dutasteride in the treatment of male patients with androgenetic alopecia. 61
26893187 2016
498
Androgenetic Alopecia: An Update of Treatment Options. 61
27554257 2016
499
Study on the Efficacy of Platelet-rich Fibrin Matrix in Hair Follicular Unit Transplantation in Androgenetic Alopecia Patients. 61
27853485 2016
500
A Comparison of the Hormonal Profile of Early Androgenetic Alopecia in Men With the Phenotypic Equivalent of Polycystic Ovarian Syndrome in Women. 61
27304785 2016
501
Cutaneuos findings in patients with predialysis chronic kidney disease. 61
27030004 2016
502
Effect of 5α-Reductase Inhibitors on Sexual Function: A Meta-Analysis and Systematic Review of Randomized Controlled Trials. 61
27475241 2016
503
Safety and Tolerability of the Dual 5-Alpha Reductase Inhibitor Dutasteride in the Treatment of Androgenetic Alopecia. 61
27489426 2016
504
Differential Expression between Human Dermal Papilla Cells from Balding and Non-Balding Scalps Reveals New Candidate Genes for Androgenetic Alopecia. 61
27060448 2016
505
Treatment of male androgenetic alopecia with topical products containing Serenoa repens extract. 61
26010505 2016
506
The association of androgenetic alopecia and insulin resistance is independent of hyperandrogenemia: A case-control study. 61
25781062 2016
507
Illness perception in patients with androgenetic alopecia and alopecia areata in China. 61
27302539 2016
508
Female sexual dysfunction in androgenetic alopecia: Case-control study. 61
28255417 2016
509
An investigation of crosstalk between Wnt/β-catenin and transforming growth factor-β signaling in androgenetic alopecia. 61
27472703 2016
510
Effect of minoxidil topical foam on frontotemporal and vertex androgenetic alopecia in men: a 104-week open-label clinical trial. 61
26387973 2016
511
The Effect of Ovine Secreted Soluble Factors on Human Dermal Papilla Cell Aggregation. 61
27625561 2016
512
[Association of eight single nucleotide polymorphisms of chromosomes 20 and X with androgenetic alopecia among ethnic Han Chinese from Yunnan]. 61
27264827 2016
513
The topical penta-peptide Gly-Pro-Ile-Gly-Ser increases the proportion of thick hair in Japanese men with androgenetic alopecia. 61
27030543 2016
514
Androgenetic alopecia. Modelling progression and regrowth. 61
27061176 2016
515
A bibliometric study of scientific literature in Scopus on botanicals for treatment of androgenetic alopecia. 61
26608588 2016
516
Androgenetic alopecia as an indicator of metabolic syndrome and cardiovascular risk. 61
26585114 2016
517
Trichotillomania: Bizzare Patern of Hair Loss at 11-Year-old Girl. 61
27477178 2016
518
Benign prostatic hyperplasia, metabolic syndrome and androgenic